1
|
He W, Shen Y, Wohlfeld K, Sears J, Li J, Pelliciari J, Walicki M, Johnston S, Baldini E, Bisogni V, Mitrano M, Dean MPM. Magnetically propagating Hund's exciton in van der Waals antiferromagnet NiPS 3. Nat Commun 2024; 15:3496. [PMID: 38664432 PMCID: PMC11045826 DOI: 10.1038/s41467-024-47852-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Accepted: 04/11/2024] [Indexed: 04/28/2024] Open
Abstract
Magnetic van der Waals (vdW) materials have opened new frontiers for realizing novel many-body phenomena. Recently NiPS3 has received intense interest since it hosts an excitonic quasiparticle whose properties appear to be intimately linked to the magnetic state of the lattice. Despite extensive studies, the electronic character, mobility, and magnetic interactions of the exciton remain unresolved. Here we address these issues by measuring NiPS3 with ultra-high energy resolution resonant inelastic x-ray scattering (RIXS). We find that Hund's exchange interactions are primarily responsible for the energy of formation of the exciton. Measuring the dispersion of the Hund's exciton reveals that it propagates in a way that is analogous to a double-magnon. We trace this unique behavior to fundamental similarities between the NiPS3 exciton hopping and spin exchange processes, underlining the unique magnetic characteristics of this novel quasiparticle.
Collapse
Affiliation(s)
- W He
- Department of Condensed Matter Physics and Materials Science, Brookhaven National Laboratory, Upton, NY, 11973, USA.
| | - Y Shen
- Department of Condensed Matter Physics and Materials Science, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - K Wohlfeld
- Institute of Theoretical Physics, Faculty of Physics, University of Warsaw, Warsaw, PL-02093, Poland
| | - J Sears
- Department of Condensed Matter Physics and Materials Science, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - J Li
- National Synchrotron Light Source II, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - J Pelliciari
- National Synchrotron Light Source II, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - M Walicki
- Institute of Theoretical Physics, Faculty of Physics, University of Warsaw, Warsaw, PL-02093, Poland
| | - S Johnston
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, TN, 37996, USA
- Institute of Advanced Materials and Manufacturing, The University of Tennessee, Knoxville, TN, 37996, USA
| | - E Baldini
- Department of Physics, The University of Texas at Austin, Austin, TX, 78712, USA
| | - V Bisogni
- National Synchrotron Light Source II, Brookhaven National Laboratory, Upton, NY, 11973, USA
| | - M Mitrano
- Department of Physics, Harvard University, Cambridge, MA, 02138, USA
| | - M P M Dean
- Department of Condensed Matter Physics and Materials Science, Brookhaven National Laboratory, Upton, NY, 11973, USA.
| |
Collapse
|
2
|
Fabbris G, Meyers D, Shen Y, Bisogni V, Zhang J, Mitchell JF, Norman MR, Johnston S, Feng J, Chiuzbăian GS, Nicolaou A, Jaouen N, Dean MPM. Resonant inelastic x-ray scattering data for Ruddlesden-Popper and reduced Ruddlesden-Popper nickelates. Sci Data 2023; 10:174. [PMID: 36991033 PMCID: PMC10060392 DOI: 10.1038/s41597-023-02079-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Accepted: 03/16/2023] [Indexed: 03/31/2023] Open
Abstract
Ruddlesden-Popper and reduced Ruddlesden-Popper nickelates are intriguing candidates for mimicking the properties of high-temperature superconducting cuprates. The degree of similarity between these nickelates and cuprates has been the subject of considerable debate. Resonant inelastic x-ray scattering (RIXS) has played an important role in exploring their electronic and magnetic excitations, but these efforts have been stymied by inconsistencies between different samples and the lack of publicly available data for detailed comparison. To address this issue, we present open RIXS data on La4Ni3O10 and La4Ni3O8.
Collapse
Affiliation(s)
- G Fabbris
- Condensed Matter Physics and Materials Science Department, Brookhaven National Laboratory, Upton, New York, 11973, USA.
- Advanced Photon Source, Argonne National Laboratory, Lemont, Illinois, 60439, USA.
| | - D Meyers
- Condensed Matter Physics and Materials Science Department, Brookhaven National Laboratory, Upton, New York, 11973, USA
- Department of Physics, Oklahoma State University, Stillwater, Oklahoma, 74078, USA
| | - Y Shen
- Condensed Matter Physics and Materials Science Department, Brookhaven National Laboratory, Upton, New York, 11973, USA
| | - V Bisogni
- National Synchrotron Light Source II, Brookhaven National Laboratory, Upton, New York, 11973, USA
| | - J Zhang
- Materials Science Division, Argonne National Laboratory, Lemont, Illinois, 60439, USA
- Institute of Crystal Materials, Shandong University, Jinan, Shandong, 250100, China
| | - J F Mitchell
- Materials Science Division, Argonne National Laboratory, Lemont, Illinois, 60439, USA
| | - M R Norman
- Materials Science Division, Argonne National Laboratory, Lemont, Illinois, 60439, USA
| | - S Johnston
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, Tennessee, 37966, USA
- Institute of Advanced Materials and Manufacturing, The University of Tennessee, Knoxville, Tennessee, 37996, USA
| | - J Feng
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique-Matière et Rayonnement, 75005, Paris, France
- Institute of Advanced Science Facilities, Shenzhen, Guangdong, 518107, China
| | - G S Chiuzbăian
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique-Matière et Rayonnement, 75005, Paris, France
- Synchrotron SOLEIL, L'Orme des Merisiers, Saint-Aubin, BP 48, 91192, Gif-sur-Yvette, France
| | - A Nicolaou
- Synchrotron SOLEIL, L'Orme des Merisiers, Saint-Aubin, BP 48, 91192, Gif-sur-Yvette, France
| | - N Jaouen
- Synchrotron SOLEIL, L'Orme des Merisiers, Saint-Aubin, BP 48, 91192, Gif-sur-Yvette, France
| | - M P M Dean
- Condensed Matter Physics and Materials Science Department, Brookhaven National Laboratory, Upton, New York, 11973, USA.
| |
Collapse
|
3
|
Pattwell M, Eldridge L, Milton M, Jethwa J, Murphy J, Slavova-Boneva V, Kiely G, Cowan-Dickie S, Pessoa Silva M, Tomlins E, Crimmin J, McWhirter A, Roe J, Ashforth K, Grayer J, Henderson B, Stanley P, Mann L, Halsted A, Kano Y, McGinn M, Droney J, Mooney J, Bateman E, Wood J, Kipps E, Johnston S, Ashurst I, Ring A, Battisti N. Nutritional needs in older adults receiving systemic treatment for breast cancer: The Royal Marsden Senior Adult Oncology Programme experience. J Geriatr Oncol 2022. [DOI: 10.1016/s1879-4068(22)00350-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
4
|
Adhikari D, Albataineh H, Androic D, Aniol KA, Armstrong DS, Averett T, Ayerbe Gayoso C, Barcus SK, Bellini V, Beminiwattha RS, Benesch JF, Bhatt H, Bhatta Pathak D, Bhetuwal D, Blaikie B, Boyd J, Campagna Q, Camsonne A, Cates GD, Chen Y, Clarke C, Cornejo JC, Covrig Dusa S, Dalton MM, Datta P, Deshpande A, Dutta D, Feldman C, Fuchey E, Gal C, Gaskell D, Gautam T, Gericke M, Ghosh C, Halilovic I, Hansen JO, Hassan O, Hauenstein F, Henry W, Horowitz CJ, Jantzi C, Jian S, Johnston S, Jones DC, Kakkar S, Katugampola S, Keppel C, King PM, King DE, Kumar KS, Kutz T, Lashley-Colthirst N, Leverick G, Liu H, Liyanage N, Mammei J, Mammei R, McCaughan M, McNulty D, Meekins D, Metts C, Michaels R, Mihovilovic M, Mondal MM, Napolitano J, Narayan A, Nikolaev D, Owen V, Palatchi C, Pan J, Pandey B, Park S, Paschke KD, Petrusky M, Pitt ML, Premathilake S, Quinn B, Radloff R, Rahman S, Rashad MNH, Rathnayake A, Reed BT, Reimer PE, Richards R, Riordan S, Roblin YR, Seeds S, Shahinyan A, Souder P, Thiel M, Tian Y, Urciuoli GM, Wertz EW, Wojtsekhowski B, Yale B, Ye T, Yoon A, Xiong W, Zec A, Zhang W, Zhang J, Zheng X. Precision Determination of the Neutral Weak Form Factor of ^{48}Ca. Phys Rev Lett 2022; 129:042501. [PMID: 35939025 DOI: 10.1103/physrevlett.129.042501] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 06/15/2022] [Accepted: 06/16/2022] [Indexed: 06/15/2023]
Abstract
We report a precise measurement of the parity-violating (PV) asymmetry A_{PV} in the elastic scattering of longitudinally polarized electrons from ^{48}Ca. We measure A_{PV}=2668±106(stat)±40(syst) parts per billion, leading to an extraction of the neutral weak form factor F_{W}(q=0.8733 fm^{-1})=0.1304±0.0052(stat)±0.0020(syst) and the charge minus the weak form factor F_{ch}-F_{W}=0.0277±0.0055. The resulting neutron skin thickness R_{n}-R_{p}=0.121±0.026(exp)±0.024(model) fm is relatively thin yet consistent with many model calculations. The combined CREX and PREX results will have implications for future energy density functional calculations and on the density dependence of the symmetry energy of nuclear matter.
Collapse
Affiliation(s)
- D Adhikari
- Idaho State University, Pocatello, Idaho 83209, USA
| | - H Albataineh
- Texas A & M University-Kingsville, Kingsville, Texas 78363, USA
| | - D Androic
- University of Zagreb, Faculty of Science, Zagreb, HR 10002, Croatia
| | - K A Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | | | - T Averett
- William and Mary, Williamsburg, Virginia 23185, USA
| | | | - S K Barcus
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | | | - J F Benesch
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Bhatt
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | | | - D Bhetuwal
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - B Blaikie
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - J Boyd
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Q Campagna
- William and Mary, Williamsburg, Virginia 23185, USA
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - G D Cates
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Y Chen
- Louisiana Tech University, Ruston, Louisiana 71272, USA
| | - C Clarke
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - J C Cornejo
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M M Dalton
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Datta
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - A Deshpande
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Dutta
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - C Feldman
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Institute for Advanced Computational Science, Stony Brook, New York 11794, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- Mississippi State University, Mississippi State, Mississippi 39762, USA
- University of Virginia, Charlottesville, Virginia 22904, USA
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23668, USA
| | - M Gericke
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - C Ghosh
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - I Halilovic
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - J-O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - O Hassan
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - F Hauenstein
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W Henry
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - C J Horowitz
- Indiana University, Bloomington, Indiana 47405, USA
| | - C Jantzi
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Jian
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Johnston
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - D C Jones
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - S Kakkar
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - S Katugampola
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - C Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - D E King
- Temple University, Philadelphia, Pennsylvania 19122, USA
- Syracuse University, Syracuse, New York 13244, USA
| | - K S Kumar
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - T Kutz
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | | | - G Leverick
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - H Liu
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - N Liyanage
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Mammei
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - R Mammei
- University of Winnipeg, Winnipeg, Manitoba R3B2E9, Canada
| | - M McCaughan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D McNulty
- Idaho State University, Pocatello, Idaho 83209, USA
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Metts
- William and Mary, Williamsburg, Virginia 23185, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Mihovilovic
- Jožef Stefan Institute, SI-1000 Ljubljana, Slovenia
- Faculty of Mathematics and Physics, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| | - M M Mondal
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
| | - J Napolitano
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A Narayan
- Veer Kunwar Singh University, Ara, Bihar 802301, India
| | - D Nikolaev
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - V Owen
- William and Mary, Williamsburg, Virginia 23185, USA
| | - C Palatchi
- University of Virginia, Charlottesville, Virginia 22904, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
| | - J Pan
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - B Pandey
- Hampton University, Hampton, Virginia 23668, USA
| | - S Park
- Mississippi State University, Mississippi State, Mississippi 39762, USA
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - K D Paschke
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Petrusky
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - M L Pitt
- Virginia Tech, Blacksburg, Virginia 24061, USA
| | - S Premathilake
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - R Radloff
- Ohio University, Athens, Ohio 45701, USA
| | - S Rahman
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - M N H Rashad
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A Rathnayake
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - B T Reed
- Indiana University, Bloomington, Indiana 47405, USA
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - R Richards
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - S Riordan
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - Y R Roblin
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Seeds
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - A Shahinyan
- A. I. Alikhanyan National Science Laboratory (Yerevan Physics Institute), Yerevan 0036, Armenia
| | - P Souder
- Syracuse University, Syracuse, New York 13244, USA
| | - M Thiel
- Institut für Kernphysik, Johannes Gutenberg-Universität, Mainz 55122, Germany
| | - Y Tian
- Syracuse University, Syracuse, New York 13244, USA
| | | | - E W Wertz
- William and Mary, Williamsburg, Virginia 23185, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Yale
- William and Mary, Williamsburg, Virginia 23185, USA
| | - T Ye
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - A Yoon
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - W Xiong
- Syracuse University, Syracuse, New York 13244, USA
- Shandong University, Qingdao, Shandong 266237, China
| | - A Zec
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - W Zhang
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - J Zhang
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
- Shandong University, Qingdao, Shandong 266237, China
| | - X Zheng
- University of Virginia, Charlottesville, Virginia 22904, USA
| |
Collapse
|
5
|
Adhikari D, Albataineh H, Androic D, Aniol K, Armstrong DS, Averett T, Ayerbe Gayoso C, Barcus S, Bellini V, Beminiwattha RS, Benesch JF, Bhatt H, Bhatta Pathak D, Bhetuwal D, Blaikie B, Boyd J, Campagna Q, Camsonne A, Cates GD, Chen Y, Clarke C, Cornejo JC, Covrig Dusa S, Dalton MM, Datta P, Deshpande A, Dutta D, Feldman C, Fuchey E, Gal C, Gaskell D, Gautam T, Gericke M, Ghosh C, Halilovic I, Hansen JO, Hauenstein F, Henry W, Horowitz CJ, Jantzi C, Jian S, Johnston S, Jones DC, Karki B, Kakkar S, Katugampola S, Keppel CE, King PM, King DE, Knauss M, Kumar KS, Kutz T, Lashley-Colthirst N, Leverick G, Liu H, Liyange N, Malace S, Mammei J, Mammei R, McCaughan M, McNulty D, Meekins D, Metts C, Michaels R, Mihovilovic M, Mondal MM, Napolitano J, Nikolaev D, Rashad MNH, Owen V, Palatchi C, Pan J, Pandey B, Park S, Paschke KD, Petrusky M, Pitt ML, Premathilake S, Puckett AJR, Quinn B, Radloff R, Rahman S, Rathnayake A, Reed BT, Reimer PE, Richards R, Riordan S, Roblin Y, Seeds S, Shahinyan A, Souder PA, Tang L, Thiel M, Tian Y, Urciuoli GM, Wertz EW, Wojtsekhowski B, Xiong W, Yale B, Ye T, Zec A, Zhang W, Zhang J, Zheng X. New Measurements of the Beam-Normal Single Spin Asymmetry in Elastic Electron Scattering over a Range of Spin-0 Nuclei. Phys Rev Lett 2022; 128:142501. [PMID: 35476486 DOI: 10.1103/physrevlett.128.142501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Revised: 01/31/2022] [Accepted: 02/04/2022] [Indexed: 06/14/2023]
Abstract
We report precision determinations of the beam-normal single spin asymmetries (A_{n}) in the elastic scattering of 0.95 and 2.18 GeV electrons off ^{12}C, ^{40}Ca, ^{48}Ca, and ^{208}Pb at very forward angles where the most detailed theoretical calculations have been performed. The first measurements of A_{n} for ^{40}Ca and ^{48}Ca are found to be similar to that of ^{12}C, consistent with expectations and thus demonstrating the validity of theoretical calculations for nuclei with Z≤20. We also report A_{n} for ^{208}Pb at two new momentum transfers (Q^{2}) extending the previous measurement. Our new data confirm the surprising result previously reported, with all three data points showing significant disagreement with the results from the Z≤20 nuclei. These data confirm our basic understanding of the underlying dynamics that govern A_{n} for nuclei containing ≲50 nucleons, but point to the need for further investigation to understand the unusual A_{n} behavior discovered for scattering off ^{208}Pb.
Collapse
Affiliation(s)
- D Adhikari
- Idaho State University, Pocatello, Idaho 83209, USA
| | - H Albataineh
- Texas A & M University - Kingsville, Kingsville, Texas 78363, USA
| | - D Androic
- University of Zagreb, Faculty of Science, Zagreb HR 10002, Croatia
| | - K Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | | | - T Averett
- William & Mary, Williamsburg, Virginia 23185, USA
| | | | - S Barcus
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | | | - J F Benesch
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Bhatt
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | | | - D Bhetuwal
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - B Blaikie
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - J Boyd
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Q Campagna
- William & Mary, Williamsburg, Virginia 23185, USA
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - G D Cates
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Y Chen
- Louisiana Tech University, Ruston, Louisiana 71272, USA
| | - C Clarke
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - J C Cornejo
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M M Dalton
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Datta
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - A Deshpande
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Dutta
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - C Feldman
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Institute for Advanced Computational Science, Stony Brook, New York 11794, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- Mississippi State University, Mississippi State, Mississippi 39762, USA
- University of Virginia, Charlottesville, Virginia 22904, USA
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23668, USA
| | - M Gericke
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - C Ghosh
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - I Halilovic
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - J-O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Henry
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - C J Horowitz
- Indiana University, Bloomington, Indiana 47405, USA
| | - C Jantzi
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Jian
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Johnston
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - D C Jones
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | - S Kakkar
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - S Katugampola
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - C E Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - D E King
- Syracuse University, Syracuse, New York 13244, USA
| | - M Knauss
- Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, USA
| | - K S Kumar
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - T Kutz
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | | | - G Leverick
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - H Liu
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - N Liyange
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Malace
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Mammei
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - R Mammei
- University of Winnipeg, Winnipeg, Manitoba R3B2E9, Canada
| | - M McCaughan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D McNulty
- Idaho State University, Pocatello, Idaho 83209, USA
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Metts
- William & Mary, Williamsburg, Virginia 23185, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Mihovilovic
- Jôzef Stefan Institute, Ljubljana 1000, Slovenia
- Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana 1000, Slovenia
| | - M M Mondal
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
| | - J Napolitano
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D Nikolaev
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - V Owen
- William & Mary, Williamsburg, Virginia 23185, USA
| | - C Palatchi
- University of Virginia, Charlottesville, Virginia 22904, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
| | - J Pan
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - B Pandey
- Hampton University, Hampton, Virginia 23668, USA
| | - S Park
- Mississippi State University, Mississippi State, Mississippi 39762, USA
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - K D Paschke
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Petrusky
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- University of Colorado Boulder, Boulder, Colorado 80309, USA
| | - M L Pitt
- Virginia Tech, Blacksburg, Virginia 24061, USA
| | - S Premathilake
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - R Radloff
- Ohio University, Athens, Ohio 45701, USA
| | - S Rahman
- University of Manitoba, Winnipeg, Manitoba R3T2N2, Canada
| | - A Rathnayake
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - B T Reed
- Indiana University, Bloomington, Indiana 47405, USA
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - R Richards
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - S Riordan
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - Y Roblin
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Seeds
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - A Shahinyan
- A. I. Alikhanyan National Science Laboratory (Yerevan Physics Institute), Yerevan 0036, Armenia
| | - P A Souder
- Syracuse University, Syracuse, New York 13244, USA
| | - L Tang
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Hampton University, Hampton, Virginia 23668, USA
| | - M Thiel
- Institut für Kernphysik, Johannes Gutenberg-Universität, Mainz 55099, Germany
| | - Y Tian
- Syracuse University, Syracuse, New York 13244, USA
| | | | - E W Wertz
- William & Mary, Williamsburg, Virginia 23185, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W Xiong
- Syracuse University, Syracuse, New York 13244, USA
| | - B Yale
- William & Mary, Williamsburg, Virginia 23185, USA
| | - T Ye
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - A Zec
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - W Zhang
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
| | - J Zhang
- Stony Brook, State University of New York, Stony Brook, New York 11794, USA
- Center for Frontiers in Nuclear Science, Stony Brook, New York 11794, USA
- Shandong University, Qingdao, Shandong 266237, China
| | - X Zheng
- University of Virginia, Charlottesville, Virginia 22904, USA
| |
Collapse
|
6
|
Rugo HS, O'Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, Gumus M, Yamashita T, Im YH, Rastogi P, Zagouri F, Song C, Campone M, San Antonio B, Shahir A, Hulstijn M, Brown J, Zimmermann A, Wei R, Johnston S, Reinisch M, Tolaney SM. Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study. Ann Oncol 2022; 33:616-627. [PMID: 35337972 DOI: 10.1016/j.annonc.2022.03.006] [Citation(s) in RCA: 36] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 03/07/2022] [Accepted: 03/11/2022] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high risk, early breast cancer demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone. Detailed safety analyses conducted at a median follow-up of 27 months and key patient-reported outcomes (PRO) are presented. PATIENTS AND METHODS The safety population included all patients who received at least one dose of study treatment (n=5591). Safety analyses included incidence, management, and outcomes of common and clinically relevant adverse events (AEs). Patient-reported health-related quality-of-life, ET symptoms, fatigue, and side effect burden were assessed. RESULTS The addition of abemaciclib to ET resulted in higher incidence of Grade≥3 AEs (49.7% vs 16.3% with ET alone), predominantly laboratory cytopenias (e.g., neutropenia [19.6%]) without clinical complications. Abemaciclib-treated patients experienced more serious adverse events (SAEs; 13.3% vs 7.8%). Discontinuation of abemaciclib and/or ET due to AEs occurred in 18.5% of patients, mainly due to Grade1/2 AEs (66.8%). AEs were managed with comedications (e.g., antidiarrheals), abemaciclib dose holds (61.7%), and/or dose reductions (43.4%). Diarrhea was generally low grade (Grade1/2: 77%); Grade2/3 events were highest in the first month (20.5%), most short-lived (≤7 days) and did not recur. Venous thromboembolic events (VTE) were higher with abemaciclib+ET (2.5%) vs ET (0.6%); in the abemaciclib arm, increased VTE risk was observed with tamoxifen vs AIs (4.3% vs 1.8%). PROs were similar between arms, including being 'bothered by side effects of treatment', except for diarrhea. At ≥3 months, most patients reporting diarrhea reported "a little bit" or "somewhat". CONCLUSION In patients with high risk EBC, adjuvant abemaciclib+ET has an acceptable safety profile and tolerability is supported by PRO findings. Most AEs were reversible and manageable with comedications and/or dose modifications, consistent with the known abemaciclib toxicity profile.
Collapse
Affiliation(s)
- H S Rugo
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
| | - J O'Shaughnessy
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas TX, USA
| | - F Boyle
- Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital, Sydney; University of Sydney, Sydney, Australia
| | - M Toi
- Kyoto University Hospital, Kyoto, Japan
| | - R Broom
- Auckland City Hospital, Auckland, New Zealand
| | - I Blancas
- Hospital Universitario Clínico San Cecilio, Granada, Spain; Medicine Department. University of Granada, Spain
| | - M Gumus
- Istanbul Medeniyet University, School of Medicine, Istanbul, Turkey
| | | | - Y-H Im
- Division of Hematology/Medical Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - P Rastogi
- University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, USA
| | - F Zagouri
- National and Kapodistrian University of Athens, Department of Clinical Therapeutics, School of Medicine, Athens, Greece
| | - C Song
- Fujian Medical University Union Hospital, Fujian, China
| | - M Campone
- Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes / Saint-Herblain, France
| | | | - A Shahir
- Eli Lilly and Company, Indianapolis, USA
| | - M Hulstijn
- Eli Lilly and Company, Indianapolis, USA
| | - J Brown
- Eli Lilly and Company, Indianapolis, USA
| | | | - Ran Wei
- Eli Lilly and Company, Indianapolis, USA
| | - S Johnston
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Reinisch
- Breast Unit, Kliniken Essen-Mitte, Essen, Germany
| | | | | |
Collapse
|
7
|
Battisti N, McGinn M, Ashurst I, Snuggs N, Crimmin J, Cowan-Dickie S, Pessoa Silva M, Eldridge L, Tomlins E, Roe J, Lister S, Grayer J, Stanley P, Mann L, Spurgeon H, Droney J, McGrath S, Hill N, Farthing L, Begum S, Waller J, Bateman E, Kipps E, Sinclair S, Johnston S, Ring A. Evaluating the needs of older adults with cancer: baseline clinical activity and considerations for the development of a Senior Adult Oncology Programme at The Royal Marsden. J Geriatr Oncol 2021. [DOI: 10.1016/s1879-4068(21)00424-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Battisti N, McGinn M, Ashurst I, Snuggs N, Crimmin J, Cowan-Dickie S, Pessoa Silva M, Eldridge L, Tomlins E, Roe J, Lister S, Grayer J, Stanley P, Mann L, Spurgeon H, Droney J, McGrath S, Hill N, Farthing L, Begum S, Joanna Waller J, Bateman E, Kipps E, Sinclair S, Johnston S, Ring A. Pioneering comprehensive oncogeriatric care in the United Kingdom: the development of a multidisciplinary Senior Adult Oncology Programme at The Royal Marsden. J Geriatr Oncol 2021. [DOI: 10.1016/s1879-4068(21)00423-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Ideta S, Johnston S, Yoshida T, Tanaka K, Mori M, Anzai H, Ino A, Arita M, Namatame H, Taniguchi M, Ishida S, Takashima K, Kojima KM, Devereaux TP, Uchida S, Fujimori A. Hybridization of Bogoliubov Quasiparticles between Adjacent CuO_{2} Layers in the Triple-Layer Cuprate Bi_{2}Sr_{2}Ca_{2}Cu_{3}O_{10+δ} Studied by Angle-Resolved Photoemission Spectroscopy. Phys Rev Lett 2021; 127:217004. [PMID: 34860085 DOI: 10.1103/physrevlett.127.217004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Revised: 07/08/2021] [Accepted: 10/20/2021] [Indexed: 06/13/2023]
Abstract
Hybridization of Bogoliubov quasiparticles (BQPs) between the CuO_{2} layers in the triple-layer cuprate high-temperature superconductor Bi_{2}Sr_{2}Cu_{2}Cu_{3}O_{10+δ} is studied by angle-resolved photoemission spectroscopy (ARPES). In the superconducting state, an anticrossing gap opens between the outer- and inner-BQP bands, which we attribute primarily to interlayer single-particle hopping with possible contributions from interlayer Cooper pairing. We find that the d-wave superconducting gap of both BQP bands smoothly develops with momentum without an abrupt jump in contrast to a previous ARPES study. Hybridization between the BQPs also gradually increases in going from the off nodal to the antinodal region, which is explained by the momentum dependence of the interlayer single-particle hopping. As possible mechanisms for the enhancement of the superconducting transition temperature, the hybridization between the BQPs as well as the combination of phonon modes of the triple CuO_{2} layers and spin fluctuations represented by a four-well model are discussed.
Collapse
Affiliation(s)
- S Ideta
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- UVSOR-III Synchrotron, Institute for Molecular Science, Okazaki 444-8585, Japan
| | - S Johnston
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, Tennessee 37996, USA
| | - T Yoshida
- Department of Human and Environmental studies, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
| | - K Tanaka
- UVSOR-III Synchrotron, Institute for Molecular Science, Okazaki 444-8585, Japan
| | - M Mori
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai 319-1195, Japan
| | - H Anzai
- Graduate School of Engineering, Osaka Prefecture University, Sakai 599-8531, Japan
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
| | - A Ino
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
- Hiroshima Synchrotron Radiation Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
- Department of Education and Creation Engineering, Kurume Institute of Technology, Fukuoka 2286-66, Japan
| | - M Arita
- Hiroshima Synchrotron Radiation Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
| | - H Namatame
- Hiroshima Synchrotron Radiation Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
| | - M Taniguchi
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
- Hiroshima Synchrotron Radiation Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
| | - S Ishida
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki 305-8568, Japan
| | - K Takashima
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - K M Kojima
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- J-PARC Center and Institute of Materials Structure Science, KEK, Tsukuba, Ibaraki 305-0801, Japan
- Centre for Molecular and Materials Science, TRIUMF, 4004 Vancouver, Canada
| | - T P Devereaux
- Geballe Laboratory for Advanced Materials, Stanford University, Stanford, California 94305, USA
- Stanford Institute for Materials and Energy Sciences, SLAC National Laboratory and Stanford University, Menlo Park, California 94025, USA
- Department of Materials Science and Engineering Stanford University, Stanford, California 94305, USA
| | - S Uchida
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki 305-8568, Japan
| | - A Fujimori
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
- Department of Applied Physics, Waseda University, Shinjuku-ku, Tokyo 169-8555, Japan
| |
Collapse
|
10
|
Harbeck N, Rastogi P, Shahir A, Johnston S, O'Shaughnessy J. Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'. Ann Oncol 2021; 33:227-228. [PMID: 34756989 DOI: 10.1016/j.annonc.2021.10.015] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Accepted: 10/22/2021] [Indexed: 11/01/2022] Open
Affiliation(s)
- N Harbeck
- Breast Center, LMU University Hospital, Munich, Germany.
| | - P Rastogi
- University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, USA
| | - A Shahir
- Eli Lilly and Company, Indianapolis, USA
| | - S Johnston
- Royal Marsden NHS Foundation Trust, London, UK
| | - J O'Shaughnessy
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA
| |
Collapse
|
11
|
O'Sullivan RJ, Aykanat T, Johnston S, Rogan G, Poole R, Prodöhl PA, de Eyto E, Primmer CR, McGinnity P, Reed TE. Correction to: 'Captive-bred Atlantic salmon released into the wild have fewer offspring than wild-bred fish and decrease population productivity'. Proc Biol Sci 2021; 288:20211244. [PMID: 34187200 DOI: 10.1098/rspb.2021.1244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Adhikari D, Albataineh H, Androic D, Aniol K, Armstrong DS, Averett T, Ayerbe Gayoso C, Barcus S, Bellini V, Beminiwattha RS, Benesch JF, Bhatt H, Bhatta Pathak D, Bhetuwal D, Blaikie B, Campagna Q, Camsonne A, Cates GD, Chen Y, Clarke C, Cornejo JC, Covrig Dusa S, Datta P, Deshpande A, Dutta D, Feldman C, Fuchey E, Gal C, Gaskell D, Gautam T, Gericke M, Ghosh C, Halilovic I, Hansen JO, Hauenstein F, Henry W, Horowitz CJ, Jantzi C, Jian S, Johnston S, Jones DC, Karki B, Katugampola S, Keppel C, King PM, King DE, Knauss M, Kumar KS, Kutz T, Lashley-Colthirst N, Leverick G, Liu H, Liyange N, Malace S, Mammei R, Mammei J, McCaughan M, McNulty D, Meekins D, Metts C, Michaels R, Mondal MM, Napolitano J, Narayan A, Nikolaev D, Rashad MNH, Owen V, Palatchi C, Pan J, Pandey B, Park S, Paschke KD, Petrusky M, Pitt ML, Premathilake S, Puckett AJR, Quinn B, Radloff R, Rahman S, Rathnayake A, Reed BT, Reimer PE, Richards R, Riordan S, Roblin Y, Seeds S, Shahinyan A, Souder P, Tang L, Thiel M, Tian Y, Urciuoli GM, Wertz EW, Wojtsekhowski B, Yale B, Ye T, Yoon A, Zec A, Zhang W, Zhang J, Zheng X. Accurate Determination of the Neutron Skin Thickness of ^{208}Pb through Parity-Violation in Electron Scattering. Phys Rev Lett 2021; 126:172502. [PMID: 33988387 DOI: 10.1103/physrevlett.126.172502] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Accepted: 03/22/2021] [Indexed: 06/12/2023]
Abstract
We report a precision measurement of the parity-violating asymmetry A_{PV} in the elastic scattering of longitudinally polarized electrons from ^{208}Pb. We measure A_{PV}=550±16(stat)±8(syst) parts per billion, leading to an extraction of the neutral weak form factor F_{W}(Q^{2}=0.00616 GeV^{2})=0.368±0.013. Combined with our previous measurement, the extracted neutron skin thickness is R_{n}-R_{p}=0.283±0.071 fm. The result also yields the first significant direct measurement of the interior weak density of ^{208}Pb: ρ_{W}^{0}=-0.0796±0.0036(exp)±0.0013(theo) fm^{-3} leading to the interior baryon density ρ_{b}^{0}=0.1480±0.0036(exp)±0.0013(theo) fm^{-3}. The measurement accurately constrains the density dependence of the symmetry energy of nuclear matter near saturation density, with implications for the size and composition of neutron stars.
Collapse
Affiliation(s)
- D Adhikari
- Idaho State University, Pocatello, ID 83209, USA
| | - H Albataineh
- Texas A & M University-Kingsville, Kingsville, TX 78363, USA
| | - D Androic
- University of Zagreb, Faculty of Science
| | - K Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | | | - T Averett
- William & Mary, Williamsburg, Virginia 23185, USA
| | | | - S Barcus
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | | | - J F Benesch
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Bhatt
- Mississippi State University, Mississippi State, MS 39762, USA
| | | | - D Bhetuwal
- Mississippi State University, Mississippi State, MS 39762, USA
| | - B Blaikie
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - Q Campagna
- William & Mary, Williamsburg, Virginia 23185, USA
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - G D Cates
- University of Virginia, Charlottesville, VA 22904, USA
| | - Y Chen
- Louisiana Tech University, Ruston, LA 71272 USA
| | - C Clarke
- Stony Brook, State University of New York, NY 11794, USA
| | - J C Cornejo
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Datta
- University of Connecticut, Storrs, CT 06269, USA
| | - A Deshpande
- Stony Brook, State University of New York, NY 11794, USA
- Center for Frontiers in Nuclear Science, NY 11794, USA
| | - D Dutta
- Mississippi State University, Mississippi State, MS 39762, USA
| | - C Feldman
- Stony Brook, State University of New York, NY 11794, USA
| | - E Fuchey
- University of Connecticut, Storrs, CT 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, VA 22904, USA
- Stony Brook, State University of New York, NY 11794, USA
- Center for Frontiers in Nuclear Science, NY 11794, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23668, USA
| | - M Gericke
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - C Ghosh
- Stony Brook, State University of New York, NY 11794, USA
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - I Halilovic
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - J-O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Henry
- Temple University, Philadelphia, PA 19122, USA
| | - C J Horowitz
- Indiana University, Bloomington, Indiana 47405, USA
| | - C Jantzi
- University of Virginia, Charlottesville, VA 22904, USA
| | - S Jian
- University of Virginia, Charlottesville, VA 22904, USA
| | - S Johnston
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - D C Jones
- Temple University, Philadelphia, PA 19122, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | - S Katugampola
- University of Virginia, Charlottesville, VA 22904, USA
| | - C Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - D E King
- Syracuse University, Syracuse, New York 13244, USA
| | - M Knauss
- Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, USA
| | - K S Kumar
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - T Kutz
- Stony Brook, State University of New York, NY 11794, USA
| | | | - G Leverick
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - H Liu
- University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA
| | - N Liyange
- University of Virginia, Charlottesville, VA 22904, USA
| | - S Malace
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - R Mammei
- University of Winnipeg, Winnipeg, MB R3B2E9 Canada
| | - J Mammei
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - M McCaughan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D McNulty
- Idaho State University, Pocatello, ID 83209, USA
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Metts
- William & Mary, Williamsburg, Virginia 23185, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M M Mondal
- Stony Brook, State University of New York, NY 11794, USA
- Center for Frontiers in Nuclear Science, NY 11794, USA
| | | | | | - D Nikolaev
- Temple University, Philadelphia, PA 19122, USA
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - V Owen
- William & Mary, Williamsburg, Virginia 23185, USA
| | - C Palatchi
- University of Virginia, Charlottesville, VA 22904, USA
- Center for Frontiers in Nuclear Science, NY 11794, USA
| | - J Pan
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - B Pandey
- Hampton University, Hampton, Virginia 23668, USA
| | - S Park
- Stony Brook, State University of New York, NY 11794, USA
| | - K D Paschke
- University of Virginia, Charlottesville, VA 22904, USA
| | - M Petrusky
- Stony Brook, State University of New York, NY 11794, USA
| | - M L Pitt
- Virginia Tech, Blacksburg, Virginia 24061, USA
| | | | | | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - R Radloff
- Ohio University, Athens, Ohio 45701, USA
| | - S Rahman
- University of Manitoba, Winnipeg, MB R3T2N2 Canada
| | - A Rathnayake
- University of Virginia, Charlottesville, VA 22904, USA
| | - B T Reed
- Indiana University, Bloomington, Indiana 47405, USA
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Il 60439
| | - R Richards
- Stony Brook, State University of New York, NY 11794, USA
| | - S Riordan
- Physics Division, Argonne National Laboratory, Lemont, Il 60439
| | - Y Roblin
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Seeds
- University of Connecticut, Storrs, CT 06269, USA
| | - A Shahinyan
- A. I. Alikhanyan National Science Laboratory (Yerevan Physics Institute), Yerevan 0036, Armenia
| | - P Souder
- Syracuse University, Syracuse, New York 13244, USA
| | - L Tang
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Hampton University, Hampton, Virginia 23668, USA
| | - M Thiel
- Institut für Kernphysik, Johannes Gutenberg-Universität, Mainz 55122, Germany
| | - Y Tian
- Syracuse University, Syracuse, New York 13244, USA
| | | | - E W Wertz
- William & Mary, Williamsburg, Virginia 23185, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Yale
- William & Mary, Williamsburg, Virginia 23185, USA
| | - T Ye
- Stony Brook, State University of New York, NY 11794, USA
| | - A Yoon
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - A Zec
- University of Virginia, Charlottesville, VA 22904, USA
| | - W Zhang
- Stony Brook, State University of New York, NY 11794, USA
| | - J Zhang
- Stony Brook, State University of New York, NY 11794, USA
- Center for Frontiers in Nuclear Science, NY 11794, USA
- Shandong University, Qingdao, Shandong 266237, China
| | - X Zheng
- University of Virginia, Charlottesville, VA 22904, USA
| |
Collapse
|
13
|
Parker CN, Harvey T, Johnston S, MacAndrew M. An exploration of knowledge of students and staff at residential aged care facilities and implications for nursing education. Nurse Educ Today 2021; 96:104639. [PMID: 33142221 DOI: 10.1016/j.nedt.2020.104639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Revised: 07/22/2020] [Accepted: 10/13/2020] [Indexed: 06/11/2023]
Abstract
BACKGROUND Advances in healthcare have contributed to population longevity with many older adults living with complex comorbidities, including those in residential aged care facilities (RACFs). Nursing staff require knowledge of gerontology, normal ageing processes and expected physiological, psychosocial, function and cognitive changes in addition to health promotion in order to provide individualised care. The complexity inherent in the medical, palliative and basic care needs of the residents makes RACFs excellent places for learning for undergraduate student nurses who undertake clinical placement as part of a Bachelor of Nursing course. Previous research has identified that knowledge of care staff is relatively poor. OBJECTIVES To explore the knowledge and misconceptions of ageing among first year undergraduate nursing students and aged care staff facilitating a placement during a clinical learning experience. DESIGN Descriptive cross-sectional design. SETTING Three clinical RACFs in Australia. PARTICIPANTS First year nursing students and staff of three different RACFs. METHOD Pre and post-test clinical placement surveys. Students and staff completed Palmore's Facts on Ageing Quiz, a 25-item tool to assess knowledge and attitudes of ageing, before commencing the clinical placement and on the last day of a two week placement. RESULTS Physiological questions were answered correctly. A knowledge deficit was evident from a sociological perspective. Negative attitudes have been found to devalue care and can directly affect the quality of practice in an undesirable way, forming a barrier to effective and therapeutic relationships with older adults, potentially impacting on patient care. CONCLUSIONS From an education provider perspective, the inclusion of activities to enrich the learning activities of nurses within RACF- inclusive of reflective activities and guidance from an expert clinical facilitator - may assist in dispelling negative attitudes and stereotypes of the older adult and increase recognition of the value of working with older adults.
Collapse
Affiliation(s)
- C N Parker
- Faculty of Health, Queensland University of Technology, Victoria Park Rd, Kelvin Grove, QLD 4059, Australia; Institute of Health & Biomedical Innovation, Queensland University of Technology, 60 Musk Ave. Kelvin Grove, QLD 4059, Australia.
| | - T Harvey
- Faculty of Health Sciences, Australian Catholic University, 1100 Nudgee Rd, Banyo, QLD 4014, Australia
| | - S Johnston
- Faculty of Health, Queensland University of Technology, Victoria Park Rd, Kelvin Grove, QLD 4059, Australia; Institute of Health & Biomedical Innovation, Queensland University of Technology, 60 Musk Ave. Kelvin Grove, QLD 4059, Australia
| | - M MacAndrew
- Faculty of Health, Queensland University of Technology, Victoria Park Rd, Kelvin Grove, QLD 4059, Australia; Institute of Health & Biomedical Innovation, Queensland University of Technology, 60 Musk Ave. Kelvin Grove, QLD 4059, Australia
| |
Collapse
|
14
|
Crespo F, Wilson R, Díaz-Jimenez M, Consuegra C, Dorado J, Barrado BG, Gosálvez J, Smit RL, Hidalgo M, Johnston S. Effect of season on individual stallion semen characteristics. Anim Reprod Sci 2020; 223:106641. [PMID: 33160762 DOI: 10.1016/j.anireprosci.2020.106641] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2020] [Revised: 10/20/2020] [Accepted: 10/21/2020] [Indexed: 11/28/2022]
Abstract
Horses are long-day seasonal breeding animals, however, with modern stallion reproductive management it is important for collection of semen during periods that are not part of the traditional breeding season. This study was conducted to examine variation in the seminal characteristics of individual stallions in Avila, Spain during 1 year with a particular emphasis on sperm DNA fragmentation. Semen was collected twice per season from a total of 20 stallions. There was a marked seasonal effect on all seminal characteristics, with the greatest on progressive motility, % membrane integrity and least for SDF in the spring months; there was also an interaction effect with respect to individual stallion, indicating that some stallions did not fit this generalised pattern for semen quality. Sperm DNA fragmentation was assessed both immediately after semen collection (T0) and following incubation of extended semen for 24 h (T24) to broadly mimic changes in SDF that might occur in the female reproductive tract. While SDF evaluated at T0 was also generally less in spring, the proportion of stallions with the least SDF values in spring increased from 45% to 60% when assessed at T24, therefore, being consistent with the importance of dynamic SDF assessment in detecting DNA damage that was not detected at T0 or cryptic DNA damage. The results from this study indicate there is individual seasonal variation among stallions in all aspects of seminal characteristics; such variation needs to be considered when prioritising stallions that are to be used for breeding.
Collapse
Affiliation(s)
- F Crespo
- Centro Militar de Cría Caballar de Ávila, Cría Caballar de las Fuerzas Armadas, Ávila, 05005, Spain
| | - R Wilson
- School of Mathematics and Physics, The University of Queensland, St Lucia, 4072, Australia
| | - M Díaz-Jimenez
- Veterinary Reproduction Group, Department of Animal Medicine and Surgery, University of Cordoba, Cordoba, 14071, Spain
| | - C Consuegra
- Veterinary Reproduction Group, Department of Animal Medicine and Surgery, University of Cordoba, Cordoba, 14071, Spain
| | - J Dorado
- Veterinary Reproduction Group, Department of Animal Medicine and Surgery, University of Cordoba, Cordoba, 14071, Spain
| | - B García Barrado
- Veterinary Reproduction Group, Department of Animal Medicine and Surgery, University of Cordoba, Cordoba, 14071, Spain
| | - J Gosálvez
- Department of Biology, Genetics Unit, Universidad Autónoma de Madrid (UAM) 20849. Madrid, Spain
| | - R Louis Smit
- School of Agriculture and Food Sciences, The University of Queensland, Gatton, 4343, Australia
| | - M Hidalgo
- Veterinary Reproduction Group, Department of Animal Medicine and Surgery, University of Cordoba, Cordoba, 14071, Spain
| | - S Johnston
- School of Agriculture and Food Sciences, The University of Queensland, Gatton, 4343, Australia.
| |
Collapse
|
15
|
Johnston S, Harbeck N, Hegg R, Toi M, Martin M, Shao Z, Campone M, Hamilton E, Sohn J, Guarneri V, Cortes J, Neven P, Boyle F, Smith I, Frenzel M, Headley D, Wei R, Cox J, O'Shaughnessy J, Rastogi P. 2MO Abemaciclib in high risk early breast cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
16
|
Seligmann JF, Wright-Hughes A, Pottinger A, Velikova G, Oughton JB, Murden G, Rizwanullah M, Price C, Passant H, Heudtlass P, Marshall H, Johnston S, Dodwell D. Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial. Clin Oncol (R Coll Radiol) 2020; 32:656-664. [PMID: 32600919 DOI: 10.1016/j.clon.2020.06.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2020] [Revised: 05/14/2020] [Accepted: 06/03/2020] [Indexed: 11/12/2022]
Abstract
AIMS Brain (central nervous system; CNS) metastases occur in 30-50% of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). A substantive evidence base for treatment is lacking, but activity with lapatinib plus capecitabine (lap-cap) has been reported. We compared lap-cap with trastuzumab plus capecitabine (tras-cap) in patients with HER2-positive MBC with CNS metastases previously treated with trastuzumab. MATERIALS AND METHODS This open-label randomised phase II screening trial aimed to randomise 130 participants over 2 years to receive lap-cap or tras-cap. Eligible patients had HER2-positive MBC with newly diagnosed or recently progressed CNS metastases; previous, or current, treatment included: trastuzumab, a taxane or anthracycline and recent completion of local cranial therapy. The primary end point was time to progression of CNS metastases within the 24-week trial period. Secondary objectives included CNS response rate, progression-free survival, steroid use for CNS symptoms and feasibility of recruitment to a large phase III trial. RESULTS Between September 2011 and October 2013, 30 participants were randomised, 16 to lap-cap and 14 to tras-cap. Recruitment to a large phase III trial was determined not to be feasible. At 24 weeks, CNS disease progression was 41.8% (95% confidence interval 16.1-67.5%) in lap-cap and 41.2% (95% confidence interval 12.8-69.6%) in tras-cap arms; progression-free survival was 44.4% (95% confidence interval 18.1-70.8%) in lap-cap and 50.0% (95% confidence interval 20.9-79.1%) in tras-cap arms. CONCLUSION Poor recruitment confirmed that a larger phase III trial would not be feasible and prohibited a preliminary evaluation of the superiority of lap-cap over tras-cap. Descriptive statistics are presented to inform the limited evidence base and future study design.
Collapse
Affiliation(s)
- J F Seligmann
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - A Wright-Hughes
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - A Pottinger
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - G Velikova
- St James's Institute of Oncology, St James University Hospital, Leeds, UK
| | - J B Oughton
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - G Murden
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - M Rizwanullah
- Department of Clinical Oncology, The Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - C Price
- Department of Medical Oncology, University Hospitals, Bristol, UK
| | - H Passant
- Department of Medical Oncology, Velindre Hospital, Cardiff, UK
| | - P Heudtlass
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - H Marshall
- Clinical Trials Research Unit, University of Leeds, Leeds, UK
| | - S Johnston
- Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK
| | - D Dodwell
- St James's Institute of Oncology, St James University Hospital, Leeds, UK; Nuffield Department of Population Health, Oxford University, Oxford, UK.
| |
Collapse
|
17
|
Lim ST, Kelly M, Johnston S. Re: 'Readability of online patient education material for the novel coronavirus disease (COVID-19): a cross-sectional health literacy study'. Public Health 2020; 190:145-146. [PMID: 33097240 PMCID: PMC7834890 DOI: 10.1016/j.puhe.2020.09.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Accepted: 09/01/2020] [Indexed: 11/17/2022]
Affiliation(s)
- S-T Lim
- Department of Surgery, University Hospital Limerick, St Nessan's Rd, Dooradoyle, Co. Limerick, V94 F858, Ireland; Midland Regional Hospital Tullamore, Arden Rd, Puttaghan, Tullamore, Co, Offaly, R35, NY51, Ireland.
| | - M Kelly
- Department of Surgery, University Hospital Limerick, St Nessan's Rd, Dooradoyle, Co, Limerick, V94 F858, Ireland
| | - S Johnston
- Midland Regional Hospital Tullamore, Arden Rd, Puttaghan, Tullamore, Co, Offaly, R35, NY51, Ireland
| |
Collapse
|
18
|
Alsabbagh MW, Kueper JK, Wong ST, Burge F, Johnston S, Peterson S, Lawson B, Chung H, Bennett M, Blackman S, McGrail K, Campbell J, Hogg W, Glazier R. Development of comparable algorithms to measure primary care indicators using administrative health data across three Canadian provinces. Int J Popul Data Sci 2020; 5:1340. [PMID: 33644408 PMCID: PMC7893851 DOI: 10.23889/ijpds.v5i1.1340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
Abstract
INTRODUCTION Performance measurement has been recognized as key to transforming primary care (PC). Yet, performance reporting in PC lags behind even though high-performing PC is foundational to an effective and efficient health care system. OBJECTIVES We used administrative data from three Canadian provinces, British Columbia, Ontario and Nova Scotia, to: 1) identify and develop a core set of PC performance indicators using administrative data and 2) examine their ability to capture PC performance. METHODS Administrative data used included Physician Billings, Discharge Abstract Database, the National Ambulatory Care and Reporting System database, Census and Vital Statistics. Indicators were compiled based on a literature review of PC indicators previously developed with administrative data available in Canada (n=158). We engaged in iterative discussions to assess data conformity, completeness, and plausibility of results in all jurisdictions. Challenges to creating comparable algorithms were examined through content analysis and research team discussions, which included clinicians, analysts, and health services researchers familiar with PC. RESULTS Our final list included 21 PC performance indicators pertaining to 1) technical care (n=4), 2) continuity of care (n=6), and 3) health services utilization (n=11). Establishing comparable algorithms across provinces was possible though time intensive. A major challenge was inconsistent data elements. Ease of data access, and a deep understanding of the data and practice context, was essential for selecting the most appropriate data elements. CONCLUSIONS This project is unique in creating algorithms to measure PC performance across provinces. It was essential to balance internal validity of the indicators within a province and external validity across provinces. The intuitive desire of having the exact same coding across provinces was infeasible due to lack of standardized PC data. Rather, a context-tailored definition was developed for each jurisdiction. This work serves as an example for developing comparable PC performance indicators across different provincial/territorial jurisdictions.
Collapse
Affiliation(s)
| | | | - ST Wong
- University of British Columbia
| | | | - S Johnston
- Bruyère Research Institute, University of Ottawa
| | | | | | | | | | | | | | | | - W Hogg
- University of Ottawa, Montfort Hospital Research Institute
| | | |
Collapse
|
19
|
McLean KA, Ahmed WUR, Akhbari M, Claireaux HA, English C, Frost J, Henshall DE, Khan M, Kwek I, Nicola M, Rehman S, Varghese S, Drake TM, Bell S, Nepogodiev D, McLean KA, Drake TM, Glasbey JC, Borakati A, Drake TM, Kamarajah S, McLean KA, Bath MF, Claireaux HA, Gundogan B, Mohan M, Deekonda P, Kong C, Joyce H, Mcnamee L, Woin E, Burke J, Khatri C, Fitzgerald JE, Harrison EM, Bhangu A, Nepogodiev D, Arulkumaran N, Bell S, Duthie F, Hughes J, Pinkney TD, Prowle J, Richards T, Thomas M, Dynes K, Patel M, Patel P, Wigley C, Suresh R, Shaw A, Klimach S, Jull P, Evans D, Preece R, Ibrahim I, Manikavasagar V, Smith R, Brown FS, Deekonda P, Teo R, Sim DPY, Borakati A, Logan AE, Barai I, Amin H, Suresh S, Sethi R, Bolton W, Corbridge O, Horne L, Attalla M, Morley R, Robinson C, Hoskins T, McAllister R, Lee S, Dennis Y, Nixon G, Heywood E, Wilson H, Ng L, Samaraweera S, Mills A, Doherty C, Woin E, Belchos J, Phan V, Chouari T, Gardner T, Goergen N, Hayes JDB, MacLeod CS, McCormack R, McKinley A, McKinstry S, Milligan W, Ooi L, Rafiq NM, Sammut T, Sinclair E, Smith M, Baker C, Boulton APR, Collins J, Copley HC, Fearnhead N, Fox H, Mah T, McKenna J, Naruka V, Nigam N, Nourallah B, Perera S, Qureshi A, Saggar S, Sun L, Wang X, Yang DD, Caroll P, Doyle C, Elangovan S, Falamarzi A, Perai KG, Greenan E, Jain D, Lang-Orsini M, Lim S, O'Byrne L, Ridgway P, Van der Laan S, Wong J, Arthur J, Barclay J, Bradley P, Edwin C, Finch E, Hayashi E, Hopkins M, Kelly D, Kelly M, McCartan N, Ormrod A, Pakenham A, Hayward J, Hitchen C, Kishore A, Martins T, Philomen J, Rao R, Rickards C, Burns N, Copeland M, Durand C, Dyal A, Ghaffar A, Gidwani A, Grant M, Gribbon C, Gruhn A, Leer M, Ahmad K, Beattie G, Beatty M, Campbell G, Donaldson G, Graham S, Holmes D, Kanabar S, Liu H, McCann C, Stewart R, Vara S, Ajibola-Taylor O, Andah EJE, Ani C, Cabdi NMO, Ito G, Jones M, Komoriyama A, Patel P, Titu L, Basra M, Gallogly P, Harinath G, Leong SH, Pradhan A, Siddiqui I, Zaat S, Ali A, Galea M, Looi WL, Ng JCK, Atkin G, Azizi A, Cargill Z, China Z, Elliot J, Jebakumar R, Lam J, Mudalige G, Onyerindu C, Renju M, Babu VS, Hussain M, Joji N, Lovett B, Mownah H, Ali B, Cresswell B, Dhillon AK, Dupaguntla YS, Hungwe C, Lowe-Zinola JD, Tsang JCH, Bevan K, Cardus C, Duggal A, Hossain S, McHugh M, Scott M, Chan F, Evans R, Gurung E, Haughey B, Jacob-Ramsdale B, Kerr M, Lee J, McCann E, O'Boyle K, Reid N, Hayat F, Hodgson S, Johnston R, Jones W, Khan M, Linn T, Long S, Seetharam P, Shaman S, Smart B, Anilkumar A, Davies J, Griffith J, Hughes B, Islam Y, Kidanu D, Mushaini N, Qamar I, Robinson H, Schramm M, Tan CY, Apperley H, Billyard C, Blazeby JM, Cannon SP, Carse S, Göpfert A, Loizidou A, Parkin J, Sanders E, Sharma S, Slade G, Telfer R, Huppatz IW, Worley E, Chandramoorthy L, Friend C, Harris L, Jain P, Karim MJ, Killington K, McGillicuddy J, Rafferty C, Rahunathan N, Rayne T, Varathan Y, Verma N, Zanichelli D, Arneill M, Brown F, Campbell B, Crozier L, Henry J, McCusker C, Prabakaran P, Wilson R, Asif U, Connor M, Dindyal S, Math N, Pagarkar A, Saleem H, Seth I, Sharma S, Standfield N, Swartbol T, Adamson R, Choi JE, El Tokhy O, Ho W, Javaid NR, Kelly M, Mehdi AS, Menon D, Plumptre I, Sturrock S, Turner J, Warren O, Crane E, Ferris B, Gadsby C, Smallwood J, Vipond M, Wilson V, Amarnath T, Doshi A, Gregory C, Kandiah K, Powell B, Spoor H, Toh C, Vizor R, Common M, Dunleavy K, Harris S, Luo C, Mesbah Z, Kumar AP, Redmond A, Skulsky S, Walsh T, Daly D, Deery L, Epanomeritakis E, Harty M, Kane D, Khan K, Mackey R, McConville J, McGinnity K, Nixon G, Ang A, Kee JY, Leung E, Norman S, Palaniappan SV, Sarathy PP, Yeoh T, Frost J, Hazeldine P, Jones L, Karbowiak M, Macdonald C, Mutarambirwa A, Omotade A, Runkel M, Ryan G, Sawers N, Searle C, Suresh S, Vig S, Ahmad A, McGartland R, Sim R, Song A, Wayman J, Brown R, Chang LH, Concannon K, Crilly C, Arnold TJ, Burgin A, Cadden F, Choy CH, Coleman M, Lim D, Luk J, Mahankali-Rao P, Prudence-Taylor AJ, Ramakrishnan D, Russell J, Fawole A, Gohil J, Green B, Hussain A, McMenamin L, McMenamin L, Tang M, Azmi F, Benchetrit S, Cope T, Haque A, Harlinska A, Holdsworth R, Ivo T, Martin J, Nisar T, Patel A, Sasapu K, Trevett J, Vernet G, Aamir A, Bird C, Durham-Hall A, Gibson W, Hartley J, May N, Maynard V, Johnson S, Wood CM, O'Brien M, Orbell J, Stringfellow TD, Tenters F, Tresidder S, Cheung W, Grant A, Tod N, Bews-Hair M, Lim ZH, Lim SW, Vella-Baldacchino M, Auckburally S, Chopada A, Easdon S, Goodson R, McCurdie F, Narouz M, Radford A, Rea E, Taylor O, Yu T, Alfa-Wali M, Amani L, Auluck I, Bruce P, Emberton J, Kumar R, Lagzouli N, Mehta A, Murtaza A, Raja M, Dennahy IS, Frew K, Given A, He YY, Karim MA, MacDonald E, McDonald E, McVinnie D, Ng SK, Pettit A, Sim DPY, Berthaume-Hawkins SD, Charnley R, Fenton K, Jones D, Murphy C, Ng JQ, Reehal R, Robinson H, Seraj SS, Shang E, Tonks A, White P, Yeo A, Chong P, Gabriel R, Patel N, Richardson E, Symons L, Aubrey-Jones D, Dawood S, Dobrzynska M, Faulkner S, Griffiths H, Mahmood F, Patel P, Perry M, Power A, Simpson R, Ali A, Brobbey P, Burrows A, Elder P, Ganyani R, Horseman C, Hurst P, Mann H, Marimuthu K, McBride S, Pilsworth E, Powers N, Stanier P, Innes R, Kersey T, Kopczynska M, Langasco N, Patel N, Rajagopal R, Atkins B, Beasley W, Lim ZC, Gill A, Ang HL, Williams H, Yogeswara T, Carter R, Fam M, Fong J, Latter J, Long M, Mackinnon S, McKenzie C, Osmanska J, Raghuvir V, Shafi A, Tsang K, Walker L, Bountra K, Coldicutt O, Fletcher D, Hudson S, Iqbal S, Bernal TL, Martin JWB, Moss-Lawton F, Smallwood J, Vipond M, Cardwell A, Edgerton K, Laws J, Rai A, Robinson K, Waite K, Ward J, Youssef H, Knight C, Koo PY, Lazarou A, Stanger S, Thorn C, Triniman MC, Botha A, Boyles L, Cumming S, Deepak S, Ezzat A, Fowler AJ, Gwozdz AM, Hussain SF, Khan S, Li H, Morrell BL, Neville J, Nitiahpapand R, Pickering O, Sagoo H, Sharma E, Welsh K, Denley S, Khan S, Agarwal M, Al-Saadi N, Bhambra R, Gupta A, Jawad ZAR, Jiao LR, Khan K, Mahir G, Singagireson S, Thoms BL, Tseu B, Wei R, Yang N, Britton N, Leinhardt D, Mahfooz M, Palkhi A, Price M, Sheikh S, Barker M, Bowley D, Cant M, Datta U, Farooqi M, Lee A, Morley G, Amin MN, Parry A, Patel S, Strang S, Yoganayagam N, Adlan A, Chandramoorthy S, Choudhary Y, Das K, Feldman M, France B, Grace R, Puddy H, Soor P, Ali M, Dhillon P, Faraj A, Gerard L, Glover M, Imran H, Kim S, Patrick Y, Peto J, Prabhudesai A, Smith R, Tang A, Vadgama N, Dhaliwal R, Ecclestone T, Harris A, Ong D, Patel D, Philp C, Stewart E, Wang L, Wong E, Xu Y, Ashaye T, Fozard T, Galloway F, Kaptanis S, Mistry P, Nguyen T, Olagbaiye F, Osman M, Philip Z, Rembacken R, Tayeh S, Theodoropoulou K, Herman A, Lau J, Saha A, Trotter M, Adeleye O, Cave D, Gunwa T, Magalhães J, Makwana S, Mason R, Parish M, Regan H, Renwick P, Roberts G, Salekin D, Sivakumar C, Tariq A, Liew I, McDade A, Stewart D, Hague M, Hudson-Peacock N, Jackson CES, James F, Pitt J, Walker EY, Aftab R, Ang JJ, Anwar S, Battle J, Budd E, Chui J, Crook H, Davies P, Easby S, Hackney E, Ho B, Imam SZ, Rammell J, Andrews H, Perry C, Schinle P, Ahmed P, Aquilina T, Balai E, Church M, Cumber E, Curtis A, Davies G, Dennis Y, Dumann E, Greenhalgh S, Kim P, King S, Metcalfe KHM, Passby L, Redgrave N, Soonawalla Z, Waters S, Zornoza A, Gulzar I, Hole J, Hull K, Ishaq H, Karaj J, Kelkar A, Love E, Patel S, Thakrar D, Vine M, Waterman A, Dib NP, Francis N, Hanson M, Ingleton R, Sadanand KS, Sukirthan N, Arnell S, Ball M, Bassam N, Beghal G, Chang A, Dawe V, George A, Huq T, Hussain A, Ikram B, Kanapeckaite L, Khan M, Ramjas D, Rushd A, Sait S, Serry M, Yardimci E, Capella S, Chenciner L, Episkopos C, Karam E, McCarthy C, Moore-Kelly W, Watson N, Ahluwalia V, Barnfield J, Ben-Gal O, Bloom I, Gharatya A, Khodatars K, Merchant N, Moonan A, Moore M, Patel K, Spiers H, Sundaram K, Turner J, Bath MF, Black J, Chadwick H, Huisman L, Ingram H, Khan S, Martin L, Metcalfe M, Sangal P, Seehra J, Thatcher A, Venturini S, Whitcroft I, Afzal Z, Brown S, Gani A, Gomaa A, Hussein N, Oh SY, Pazhaniappan N, Sharkey E, Sivagnanasithiyar T, Williams C, Yeung J, Cruddas L, Gurjar S, Pau A, Prakash R, Randhawa R, Chen L, Eiben I, Naylor M, Osei-Bordom D, Trenear R, Bannard-Smith J, Griffiths N, Patel BY, Saeed F, Abdikadir H, Bennett M, Church R, Clements SE, Court J, Delvi A, Hubert J, Macdonald B, Mansour F, Patel RR, Perris R, Small S, Betts A, Brown N, Chong A, Croitoru C, Grey A, Hickland P, Ho C, Hollington D, McKie L, Nelson AR, Stewart H, Eiben P, Nedham M, Ali I, Brown T, Cumming S, Hunt C, Joyner C, McAlinden C, Roberts J, Rogers D, Thachettu A, Tyson N, Vaughan R, Verma N, Yasin T, Andrew K, Bhamra N, Leong S, Mistry R, Noble H, Rashed F, Walker NR, Watson L, Worsfold M, Yarham E, Abdikadir H, Arshad A, Barmayehvar B, Cato L, Chan-lam N, Do V, Leong A, Sheikh Z, Zheleniakova T, Coppel J, Hussain ST, Mahmood R, Nourzaie R, Prowle J, Sheik-Ali S, Thomas A, Alagappan A, Ashour R, Bains H, Diamond J, Gordon J, Ibrahim B, Khalil M, Mittapalli D, Neo YN, Patil P, Peck FS, Reza N, Swan I, Whyte M, Chaudhry S, Hernon J, Khawar H, O'Brien J, Pullinger M, Rothnie K, Ujjal S, Bhatte S, Curtis J, Green S, Mayer A, Watkinson G, Chapple K, Hawthorne T, Khaliq M, Majkowski L, Malik TAM, Mclauchlan K, En BNW, Parton S, Robinson SD, Saat MI, Shurovi BN, Varatharasasingam K, Ward AE, Behranwala K, Bertelli M, Cohen J, Duff F, Fafemi O, Gupta R, Manimaran M, Mayhew J, Peprah D, Wong MHY, Farmer N, Houghton C, Kandhari N, Khan K, Ladha D, Mayes J, McLennan F, Panahi P, Seehra H, Agrawal R, Ahmed I, Ali S, Birkinshaw F, Choudhry M, Gokani S, Harrogate S, Jamal S, Nawrozzadeh F, Swaray A, Szczap A, Warusavitarne J, Abdalla M, Asemota N, Cullum R, Hartley M, Maxwell-Armstrong C, Mulvenna C, Phillips J, Yule A, Ahmed L, Clement KD, Craig N, Elseedawy E, Gorman D, Kane L, Livie J, Livie V, Moss E, Naasan A, Ravi F, Shields P, Zhu Y, Archer M, Cobley H, Dennis R, Downes C, Guevel B, Lamptey E, Murray H, Radhakrishnan A, Saravanabavan S, Sardar M, Shaw C, Tilliridou V, Wright R, Ye W, Alturki N, Helliwell R, Jones E, Kelly D, Lambotharan S, Scott K, Sivakumar R, Victor L, Boraluwe-Rallage H, Froggatt P, Haynes S, Hung YMA, Keyte A, Matthews L, Evans E, Haray P, John I, Mathivanan A, Morgan L, Oji O, Okorocha C, Rutherford A, Spiers H, Stageman N, Tsui A, Whitham R, Amoah-Arko A, Cecil E, Dietrich A, Fitzpatrick H, Guy C, Hair J, Hilton J, Jawad L, McAleer E, Taylor Z, Yap J, Akhbari M, Debnath D, Dhir T, Elbuzidi M, Elsaddig M, Glace S, Khawaja H, Koshy R, Lal K, Lobo L, McDermott A, Meredith J, Qamar MA, Vaidya A, Acquaah F, Barfi L, Carter N, Gnanappiragasam D, Ji C, Kaminski F, Lawday S, Mackay K, Sulaiman SK, Webb R, Ananthavarathan P, Dalal F, Farrar E, Hashemi R, Hossain M, Jiang J, Kiandee M, Lex J, Mason L, Matthews JH, McGeorge E, Modhwadia S, Pinkney T, Radotra A, Rickard L, Rodman L, Sales A, Tan KL, Bachi A, Bajwa DS, Battle J, Brown LR, Butler A, Calciu A, Davies E, Gardner I, Girdlestone T, Ikogho O, Keelan G, O'Loughlin P, Tam J, Elias J, Ngaage M, Thompson J, Bristow S, Brock E, Davis H, Pantelidou M, Sathiyakeerthy A, Singh K, Chaudhry A, Dickson G, Glen P, Gregoriou K, Hamid H, Mclean A, Mehtaji P, Neophytou G, Potts S, Belgaid DR, Burke J, Durno J, Ghailan N, Hanson M, Henshaw V, Nazir UR, Omar I, Riley BJ, Roberts J, Smart G, Van Winsen K, Bhatti A, Chan M, D'Auria M, Green S, Keshvala C, Li H, Maxwell-Armstrong C, Michaelidou M, Simmonds L, Smith C, Wimalathasan A, Abbas J, Cairns C, Chin YR, Connelly A, Moug S, Nair A, Svolkinas D, Coe P, Subar D, Wang H, Zaver V, Brayley J, Cookson P, Cunningham L, Gaukroger A, Ho M, Hough A, King J, O'Hagan D, Widdison A, Brown R, Brown B, Chavan A, Francis S, Hare L, Lund J, Malone N, Mavi B, McIlwaine A, Rangarajan S, Abuhussein N, Campbell HS, Daniels J, Fitzgerald I, Mansfield S, Pendrill A, Robertson D, Smart YW, Teng T, Yates J, Belgaumkar A, Katira A, Kossoff J, Kukran S, Laing C, Mathew B, Mohamed T, Myers S, Novell R, Phillips BL, Thomas M, Turlejski T, Turner S, Varcada M, Warren L, Wynell-Mayow W, Church R, Linley-Adams L, Osborn G, Saunders M, Spencer R, Srikanthan M, Tailor S, Tullett A, Ali M, Al-Masri S, Carr G, Ebhogiaye O, Heng S, Manivannan S, Manley J, McMillan LE, Peat C, Phillips B, Thomas S, Whewell H, Williams G, Bienias A, Cope EA, Courquin GR, Day L, Garner C, Gimson A, Harris C, Markham K, Moore T, Nadin T, Phillips C, Subratty SM, Brown K, Dada J, Durbacz M, Filipescu T, Harrison E, Kennedy ED, Khoo E, Kremel D, Lyell I, Pronin S, Tummon R, Ventre C, Walls L, Wootton E, Akhtar A, Davies E, El-Sawy D, Farooq M, Gaddah M, Griffiths H, Katsaiti I, Khadem N, Leong K, Williams I, Chean CS, Chudek D, Desai H, Ellerby N, Hammad A, Malla S, Murphy B, Oshin O, Popova P, Rana S, Ward T, Abbott TEF, Akpenyi O, Edozie F, El Matary R, English W, Jeyabaladevan S, Morgan C, Naidu V, Nicholls K, Peroos S, Prowle J, Sansome S, Torrance HD, Townsend D, Brecher J, Fung H, Kazmi Z, Outlaw P, Pursnani K, Ramanujam N, Razaq A, Sattar M, Sukumar S, Tan TSE, Chohan K, Dhuna S, Haq T, Kirby S, Lacy-Colson J, Logan P, Malik Q, McCann J, Mughal Z, Sadiq S, Sharif I, Shingles C, Simon A, Burnage S, Chan SSN, Craig ARJ, Duffield J, Dutta A, Eastwood M, Iqbal F, Mahmood F, Mahmood W, Patel C, Qadeer A, Robinson A, Rotundo A, Schade A, Slade RD, De Freitas M, Kinnersley H, McDowell E, Moens-Lecumberri S, Ramsden J, Rockall T, Wiffen L, Wright S, Bruce C, Francois V, Hamdan K, Limb C, Lunt AJ, Manley L, Marks M, Phillips CFE, Agnew CJF, Barr CJ, Benons N, Hart SJ, Kandage D, Krysztopik R, Mahalingam P, Mock J, Rajendran S, Stoddart MT, Clements B, Gillespie H, Lee S, McDougall R, Murray C, O'Loane R, Periketi S, Tan S, Amoah R, Bhudia R, Dudley B, Gilbert A, Griffiths B, Khan H, McKigney N, Roberts B, Samuel R, Seelarbokus A, Stubbing-Moore A, Thompson G, Williams P, Ahmed N, Akhtar R, Chandler E, Chappelow I, Gil H, Gower T, Kale A, Lingam G, Rutler L, Sellahewa C, Sheikh A, Stringer H, Taylor R, Aglan H, Ashraf MR, Choo S, Das E, Epstein J, Gentry R, Mills D, Poolovadoo Y, Ward N, Bull K, Cole A, Hack J, Khawari S, Lake C, Mandishona T, Perry R, Sleight S, Sultan S, Thornton T, Williams S, Arif T, Castle A, Chauhan P, Chesner R, Eilon T, Kamarajah S, Kambasha C, Lock L, Loka T, Mohammad F, Motahariasl S, Roper L, Sadhra SS, Sheikh A, Toma T, Wadood Q, Yip J, Ainger E, Busti S, Cunliffe L, Flamini T, Gaffing S, Moorcroft C, Peter M, Simpson L, Stokes E, Stott G, Wilson J, York J, Yousaf A, Borakati A, Brown M, Goaman A, Hodgson B, Ijeomah A, Iroegbu U, Kaur G, Lowe C, Mahmood S, Sattar Z, Sen P, Szuman A, Abbas N, Al-Ausi M, Anto N, Bhome R, Eccles L, Elliott J, Hughes EJ, Jones A, Karunatilleke AS, Knight JS, Manson CCF, Mekhail I, Michaels L, Noton TM, Okenyi E, Reeves T, Yasin IH, Banfield DA, Harris R, Lim D, Mason-Apps C, Roe T, Sandhu J, Shafiq N, Stickler E, Tam JP, Williams LM, Ainsworth P, Boualbanat Y, Doull C, Egan E, Evans L, Hassanin K, Ninkovic-Hall G, Odunlami W, Shergill M, Traish M, Cummings D, Kershaw S, Ong J, Reid F, Toellner H, Alwandi A, Amer M, George D, Haynes K, Hughes K, Peakall L, Premakumar Y, Punjabi N, Ramwell A, Sawkins H, Ashwood J, Baker A, Baron C, Bhide I, Blake E, De Cates C, Esmail R, Hosamuddin H, Kapp J, Nguru N, Raja M, Thomson F, Ahmed H, Aishwarya G, Al-Huneidi R, Ali S, Aziz R, Burke D, Clarke B, Kausar A, Maskill D, Mecia L, Myers L, Smith ACD, Walker G, Wroe N, Donohoe C, Gibbons D, Jordan P, Keogh C, Kiely A, Lalor P, McCrohan M, Powell C, Foley MP, Reynolds J, Silke E, Thorpe O, Kong JTH, White C, Ali Q, Dalrymple J, Ge Y, Khan H, Luo RS, Paine H, Paraskeva B, Parker L, Pillai K, Salciccioli J, Selvadurai S, Sonagara V, Springford LR, Tan L, Appleton S, Leadholm N, Zhang Y, Ahern D, Cotter M, Cremen S, Durrigan T, Flack V, Hrvacic N, Jones H, Jong B, Keane K, O'Connell PR, O'sullivan J, Pek G, Shirazi S, Barker C, Brown A, Carr W, Chen Y, Guillotte C, Harte J, Kokayi A, Lau K, McFarlane S, Morrison S, Broad J, Kenefick N, Makanji D, Printz V, Saito R, Thomas O, Breen H, Kirk S, Kong CH, O'Kane A, Eddama M, Engledow A, Freeman SK, Frost A, Goh C, Lee G, Poonawala R, Suri A, Taribagil P, Brown H, Christie S, Dean S, Gravell R, Haywood E, Holt F, Pilsworth E, Rabiu R, Roscoe HW, Shergill S, Sriram A, Sureshkumar A, Tan LC, Tanna A, Vakharia A, Bhullar S, Brannick S, Dunne E, Frere M, Kerin M, Kumar KM, Pratumsuwan T, Quek R, Salman M, Van Den Berg N, Wong C, Ahluwalia J, Bagga R, Borg CM, Calabria C, Draper A, Farwana M, Joyce H, Khan A, Mazza M, Pankin G, Sait MS, Sandhu N, Virani N, Wong J, Woodhams K, Croghan N, Ghag S, Hogg G, Ismail O, John N, Nadeem K, Naqi M, Noe SM, Sharma A, Tan S, Begum F, Best R, Collishaw A, Glasbey J, Golding D, Gwilym B, Harrison P, Jackman T, Lewis N, Luk YL, Porter T, Potluri S, Stechman M, Tate S, Thomas D, Walford B, Auld F, Bleakley A, Johnston S, Jones C, Khaw J, Milne S, O'Neill S, Singh KKR, Smith R, Swan A, Thorley N, Yalamarthi S, Yin ZD, Ali A, Balian V, Bana R, Clark K, Livesey C, McLachlan G, Mohammad M, Pranesh N, Richards C, Ross F, Sajid M, Brooke M, Francombe J, Gresly J, Hutchinson S, Kerrigan K, Matthews E, Nur S, Parsons L, Sandhu A, Vyas M, White F, Zulkifli A, Zuzarte L, Al-Mousawi A, Arya J, Azam S, Yahaya AA, Gill K, Hallan R, Hathaway C, Leptidis I, McDonagh L, Mitrasinovic S, Mushtaq N, Pang N, Peiris GB, Rinkoff S, Chan L, Christopher E, Farhan-Alanie MMH, Gonzalez-Ciscar A, Graham CJ, Lim H, McLean KA, Paterson HM, Rogers A, Roy C, Rutherford D, Smith F, Zubikarai G, Al-Khudairi R, Bamford M, Chang M, Cheng J, Hedley C, Joseph R, Mitchell B, Perera S, Rothwell L, Siddiqui A, Smith J, Taylor K, Wright OW, Baryan HK, Boyd G, Conchie H, Cox L, Davies J, Gardner S, Hill N, Krishna K, Lakin F, Scotcher S, Alberts J, Asad M, Barraclough J, Campbell A, Marshall D, Wakeford W, Cronbach P, D'Souza F, Gammeri E, Houlton J, Hall M, Kethees A, Patel R, Perera M, Prowle J, Shaid M, Webb E, Beattie S, Chadwick M, El-Taji O, Haddad S, Mann M, Patel M, Popat K, Rimmer L, Riyat H, Smith H, Anandarajah C, Cipparrone M, Desai K, Gao C, Goh ET, Howlader M, Jeffreys N, Karmarkar A, Mathew G, Mukhtar H, Ozcan E, Renukanthan A, Sarens N, Sinha C, Woolley A, Bogle R, Komolafe O, Loo F, Waugh D, Zeng R, Crewe A, Mathias J, Mills A, Owen A, Prior A, Saunders I, Baker A, Crilly L, McKeon J, Ubhi HK, Adeogun A, Carr R, Davison C, Devalia S, Hayat A, Karsan RB, Osborne C, Scott K, Weegenaar C, Wijeyaratne M, Babatunde F, Barnor-Ahiaku E, Beattie G, Chitsabesan P, Dixon O, Hall N, Ilenkovan N, Mackrell T, Nithianandasivam N, Orr J, Palazzo F, Saad M, Sandland-Taylor L, Sherlock J, Ashdown T, Chandler S, Garsaa T, Lloyd J, Loh SY, Ng S, Perkins C, Powell-Chandler A, Smith F, Underhill R. Perioperative intravenous contrast administration and the incidence of acute kidney injury after major gastrointestinal surgery: prospective, multicentre cohort study. Br J Surg 2020; 107:1023-1032. [PMID: 32026470 DOI: 10.1002/bjs.11453] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Revised: 09/21/2019] [Accepted: 11/08/2019] [Indexed: 01/14/2023]
Abstract
BACKGROUND This study aimed to determine the impact of preoperative exposure to intravenous contrast for CT and the risk of developing postoperative acute kidney injury (AKI) in patients undergoing major gastrointestinal surgery. METHODS This prospective, multicentre cohort study included adults undergoing gastrointestinal resection, stoma reversal or liver resection. Both elective and emergency procedures were included. Preoperative exposure to intravenous contrast was defined as exposure to contrast administered for the purposes of CT up to 7 days before surgery. The primary endpoint was the rate of AKI within 7 days. Propensity score-matched models were adjusted for patient, disease and operative variables. In a sensitivity analysis, a propensity score-matched model explored the association between preoperative exposure to contrast and AKI in the first 48 h after surgery. RESULTS A total of 5378 patients were included across 173 centres. Overall, 1249 patients (23·2 per cent) received intravenous contrast. The overall rate of AKI within 7 days of surgery was 13·4 per cent (718 of 5378). In the propensity score-matched model, preoperative exposure to contrast was not associated with AKI within 7 days (odds ratio (OR) 0·95, 95 per cent c.i. 0·73 to 1·21; P = 0·669). The sensitivity analysis showed no association between preoperative contrast administration and AKI within 48 h after operation (OR 1·09, 0·84 to 1·41; P = 0·498). CONCLUSION There was no association between preoperative intravenous contrast administered for CT up to 7 days before surgery and postoperative AKI. Risk of contrast-induced nephropathy should not be used as a reason to avoid contrast-enhanced CT.
Collapse
|
20
|
Bisson C, Castellano T, Zhao D, Johnston S, Gunderson C. Impact of race on management, treatment, and outcomes in vulvar cancer. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2019.11.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
21
|
Vaughan-Shaw PG, Zgaga L, Ooi LY, Theodoratou E, Timofeeva M, Svinti V, Walker M, O'Sullivan F, Ewing A, Johnston S, Din FVN, Campbell H, Farrington SM, Dunlop MG. Low plasma vitamin D is associated with adverse colorectal cancer survival after surgical resection, independent of systemic inflammatory response. Gut 2020; 69:103-111. [PMID: 31023832 PMCID: PMC6943245 DOI: 10.1136/gutjnl-2018-317922] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Revised: 03/04/2019] [Accepted: 03/26/2019] [Indexed: 12/31/2022]
Abstract
OBJECTIVE We assessed the effect of surgical resection of colorectal cancer (CRC) on perioperative plasma vitamin D (25OHD) and C-reactive protein (CRP) level. We investigated the relationship between circulating vitamin D level and CRC survival. DESIGN We sequentially sampled 92 patients undergoing CRC resection, and measured plasma 25OHD and CRP. For survival analyses, we assayed 25OHD and CRP in two temporally distinct CRC patient cohorts (n=2006, n=2100) and investigated the association between survival outcome, circulating vitamin D and systemic inflammatory response. RESULTS Serial sampling revealed a postoperative fall (mean 17.3 nmol/L; p=3.6e-9) in plasma 25OHD (nadir days 1-2). CRP peaked 3-5 days postoperatively (143.1 mg/L; p=1.4e-12), yet the postoperative fall in 25OHD was independent of CRP. In cohort analyses, 25OHD was lower in the 12 months following operation (mean=48.8 nmol/L) than preoperatively (54.8 nmol/L; p=1.2e-5) recovering after 24 months (52.2 nmol/L; p=0.002). Survival analysis in American Joint Committee on Cancer stages I-III demonstrated associations between 25OHD tertile and CRC mortality (HR=0.69; 95% CI 0.46 to 0.91) and all-cause mortality (HR=0.68; 95% CI 0.50 to 0.85), and was independent of CRP. We observed interaction effects between plasma 25OHD and rs11568820 genotype (functional VDR polymorphism) with a strong protective effect of higher 25OHD only in patients with GG genotype (HR=0.51; 95% CI 0.21 to 0.81). We developed an online tool for predicted survival (https://apps.igmm.ed.ac.uk/mortalityCalculator/) that incorporates 25OHD with clinically useful predictive performance (area under the curve 0.77). CONCLUSIONS CRC surgery induces a fall in circulating 25OHD. Plasma 25OHD level is a prognostic biomarker with low 25OHD associated with poorer survival, particularly in those with rs11568820 GG genotype. A randomised trial of vitamin D supplementation after CRC surgery has compelling rationale.
Collapse
Affiliation(s)
- P G Vaughan-Shaw
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - L Zgaga
- Department of Public Health and Primary Care, Trinity College Dublin, Dublin 24, Republic of Ireland
| | - L Y Ooi
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - E Theodoratou
- Centre for Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
- Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - M Timofeeva
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - V Svinti
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - M Walker
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - F O'Sullivan
- Department of Public Health and Primary Care, Trinity College Dublin, Dublin 24, Republic of Ireland
| | - A Ewing
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - S Johnston
- Specialist Endocrine Laboratory, NHS Greater Glasgow and Clyde, Glasgow, UK
| | - F V N Din
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - H Campbell
- Centre for Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
| | - S M Farrington
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - M G Dunlop
- Cancer Research UK Edinburgh Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
22
|
Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol 2019; 29:888-894. [PMID: 29360932 PMCID: PMC5913649 DOI: 10.1093/annonc/mdy012] [Citation(s) in RCA: 90] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background Patient-reported outcomes are integral in benefit-risk assessments of new treatment regimens. The PALOMA-2 study provides the largest body of evidence for patient-reported health-related quality of life (QOL) for patients with metastatic breast cancer (MBC) receiving first-line endocrine-based therapy (palbociclib plus letrozole and letrozole alone). Patients and methods Treatment-naïve postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) MBC were randomized 2 : 1 to palbociclib plus letrozole (n = 444) or placebo plus letrozole (n = 222). Patient-reported outcomes were assessed at baseline, day 1 of cycles 2 and 3, and day 1 of every other cycle from cycle 5 using the Functional Assessment of Cancer Therapy (FACT)-Breast and EuroQOL 5 dimensions (EQ-5D) questionnaires. Results As of 26 February 2016, the median duration of follow-up was 23 months. Baseline scores were comparable between the two treatment arms. No significant between-arm differences were observed in change from baseline in FACT-Breast Total, FACT-General Total, or EQ-5D scores. Significantly greater improvement in pain scores was observed in the palbociclib plus letrozole arm (-0.256 versus -0.098; P = 0.0183). In both arms, deterioration of FACT-Breast Total score was significantly delayed in patients without progression versus those with progression and patients with partial or complete response versus those without. No significant difference was observed in FACT-Breast and EQ-5D index scores in patients with and without neutropenia. Conclusions Overall, women with MBC receiving first-line endocrine therapy have a good QOL. The addition of palbociclib to letrozole maintains health-related QOL and improves pain scores in treatment-naïve postmenopausal patients with ER+/HER2- MBC compared with letrozole alone. Significantly greater delay in deterioration of health-related QOL was observed in patients without progression versus those who progressed and in patients with an objective response versus non-responders. ClinicalTrials.gov: NCT01740427 (https://clinicaltrials.gov/ct2/show/NCT01740427).
Collapse
Affiliation(s)
- H S Rugo
- Department of Medicine (Hematology/Oncology), University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.
| | - V Diéras
- Department of Medical Oncology, Institut Curie, Paris, France
| | - K A Gelmon
- Department of Medical Oncology, British Columbia Cancer Agency-Vancouver Centre, Vancouver, Canada
| | - R S Finn
- Division of Hematology/Oncology, University of California, Los Angeles, USA
| | - D J Slamon
- Division of Hematology/Oncology, University of California, Los Angeles, USA
| | - M Martin
- Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, GEICAM, Universidad Complutense, Madrid, Spain
| | - P Neven
- Department of Oncology, Universitair Ziekenhuis Leuven-Campus Gasthuisberg, Leuven, Belgium
| | - Y Shparyk
- Department of Chemotherapy, Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine
| | - A Mori
- Global Product Developmen, Clinical, Pfizer s.r.l., Milan, Italy
| | - D R Lu
- Global Product Developmen, Statistics, Pfizer Inc., La Jolla, USA
| | | | | | - S Iyer
- Global Outcomes and Evidence, Pfizer Inc., New York, USA
| | - S Johnston
- Department of Medical Oncology, The Royal Marsden NHS Foundation, London, UK
| | - J Ettl
- Department of Obstetrics and Gynecology, Frauenklinik und Poliklinik Klinikum Rechts der Isar, Technische Universität München, München, Germany
| | - N Harbeck
- Department of Obstetrics and Gynecology, Brustzentrum der Universität München (LMU), München, Germany
| |
Collapse
|
23
|
Martín M, Johnston S, Huober J, Di Leo A, Sohn J, Andre V, Martin H, Hardebeck M, Goetz M. MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2- advanced breast cancer (ABC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.021] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Tan M, Johnston S, Nicholls J, Gompels M. Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients? HIV Med 2019; 20:634-637. [PMID: 31338933 PMCID: PMC6790693 DOI: 10.1111/hiv.12781] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/10/2019] [Indexed: 11/27/2022]
Abstract
OBJECTIVES The aim of the study was to evaluate the efficacy of dual therapy with lamivudine (3TC), with dose adjustment for renal function, and dolutegravir (DTG) in a subgroup of patients fully suppressed on treatment who were switched because of concerns about comorbidity and toxicity on their current triple drug regimen. METHODS A retrospective evaluation of clinical and pathological parameters from an electronic patient record from a single centre was carried out. RESULTS There were no virological failures in 52 patients with a median age of 60.5 years. The median duration of follow-on dual therapy was 2.29 years (28 months; range 1.10-3.34 years). In 25 of 52 (48%) cases, the dose of 3TC was adjusted taking into account reduced renal function, and none of these patients experienced virological failure. Four additional patients discontinued early, because of side effects of the switch, with no failure. CONCLUSIONS This retrospective review suggests that 3TC and DTG may be effective in controlling viral load in older patients with comorbidities. This regimen appears to be a useful option in the context of comorbidities (including renal impairment) and polypharmacy in older patients. However, this review has been conducted in one centre and in a small population of patients. Therefore, further multicentre trials involving larger populations of patients are needed.
Collapse
Affiliation(s)
- M Tan
- University of Bristol Medical School, Bristol, UK
| | | | | | - M Gompels
- North Bristol NHS Trust, Bristol, UK
| |
Collapse
|
25
|
Hattawy M, Baltzell NA, Dupré R, Bültmann S, De Vita R, El Alaoui A, El Fassi L, Egiyan H, Girod FX, Guidal M, Hafidi K, Jenkins D, Liuti S, Perrin Y, Stepanyan S, Torayev B, Voutier E, Adhikari S, Angelini G, Ayerbe Gayoso C, Barion L, Battaglieri M, Bedlinskiy I, Biselli AS, Bossù F, Brooks W, Cao F, Carman DS, Celentano A, Chatagnon P, Chetry T, Ciullo G, Clark L, Cole PL, Contalbrigo M, Crede V, D'Angelo A, Dashyan N, De Sanctis E, Defurne M, Deur A, Diehl S, Djalali C, Ehrhart M, Eugenio P, Fegan S, Filippi A, Forest TA, Fradi A, Garçon M, Gavalian G, Gevorgyan N, Gilfoyle GP, Giovanetti KL, Golovatch E, Gothe RW, Griffioen KA, Harrison N, Hauenstein F, Hayward TB, Heddle D, Hicks K, Holtrop M, Ilieva Y, Ireland DG, Isupov EL, Jo HS, Johnston S, Keller D, Khachatryan G, Khachatryan M, Khanal A, Khandaker M, Kim CW, Kim W, Klein FJ, Kubarovsky V, Kuhn SE, Lanza L, L Kabir M, Lenisa P, Livingston K, MacGregor IJD, Marchand D, Markov N, Mayer M, McKinnon B, Meziani ZE, Mineeva T, Mirazita M, Montgomery RA, Munoz Camacho C, Nadel-Turonski P, Niccolai S, Ostrovidov AI, Pappalardo LL, Paremuzyan R, Pasyuk E, Pogorelko O, Poudel J, Prok Y, Protopopescu D, Ripani M, Riser D, Rizzo A, Rosner G, Rossi P, Sabatié F, Salgado C, Schumacher RA, Sharabian YG, Skorodumina I, Sokhan D, Soto O, Sparveris N, Strauch S, Taiuti M, Tan JA, Tyler N, Ungaro M, Voskanyan H, Wang R, Watts DP, Wei X, Weinstein LB, Wood MH, Zachariou N, Zhang J, Zhao ZW. Exploring the Structure of the Bound Proton with Deeply Virtual Compton Scattering. Phys Rev Lett 2019; 123:032502. [PMID: 31386486 DOI: 10.1103/physrevlett.123.032502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 03/12/2019] [Indexed: 06/10/2023]
Abstract
In the past two decades, deeply virtual Compton scattering of electrons has been successfully used to advance our knowledge of the partonic structure of the free proton and investigate correlations between the transverse position and the longitudinal momentum of quarks inside the nucleon. Meanwhile, the structure of bound nucleons in nuclei has been studied in inclusive deep-inelastic lepton scattering experiments off nuclear targets, showing a significant difference in longitudinal momentum distribution of quarks inside the bound nucleon, known as the EMC effect. In this Letter, we report the first beam spin asymmetry (BSA) measurement of exclusive deeply virtual Compton scattering off a proton bound in ^{4}He. The data used here were accumulated using a 6 GeV longitudinally polarized electron beam incident on a pressurized ^{4}He gaseous target placed within the CLAS spectrometer in Hall-B at the Thomas Jefferson National Accelerator Facility. The azimuthal angle (ϕ) dependence of the BSA was studied in a wide range of virtual photon and scattered proton kinematics. The Q^{2}, x_{B}, and t dependencies of the BSA on the bound proton are compared with those on the free proton. In the whole kinematical region of our measurements, the BSA on the bound proton is smaller by 20% to 40%, indicating possible medium modification of its partonic structure.
Collapse
Affiliation(s)
- M Hattawy
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - N A Baltzell
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Old Dominion University, Norfolk, Virginia 23529, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - R Dupré
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - S Bültmann
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - R De Vita
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - A El Alaoui
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - L El Fassi
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - H Egiyan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F X Girod
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Guidal
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - K Hafidi
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - D Jenkins
- Virginia Tech, Blacksburg, Virginia 24061-0435, USA
| | - S Liuti
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - Y Perrin
- LPSC, Université Grenoble-Alpes, CNRS/IN2P3, 38026 Grenoble, France
| | - S Stepanyan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Torayev
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - E Voutier
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
- LPSC, Université Grenoble-Alpes, CNRS/IN2P3, 38026 Grenoble, France
| | - S Adhikari
- Florida International University, Miami, Florida 33199, USA
| | | | - C Ayerbe Gayoso
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - L Barion
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | | | - I Bedlinskiy
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - A S Biselli
- Fairfield University, Fairfield Connecticut 06824, USA
| | - F Bossù
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - W Brooks
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - F Cao
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - D S Carman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Celentano
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - P Chatagnon
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - G Ciullo
- Universita' di Ferrara, 44121 Ferrara, Italy
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - L Clark
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - P L Cole
- Idaho State University, Pocatello, Idaho 83209, USA
- Lamar University, 4400 MLK Boulevard, P.O. Box 10009, Beaumont, Texas 77710, USA
| | | | - V Crede
- Florida State University, Tallahassee, Florida 32306, USA
| | - A D'Angelo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Universita' di Roma Tor Vergata, 00133 Rome, Italy
| | - N Dashyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E De Sanctis
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - M Defurne
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - A Deur
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Diehl
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Djalali
- Ohio University, Athens, Ohio 45701, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Ehrhart
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - P Eugenio
- Florida State University, Tallahassee, Florida 32306, USA
| | - S Fegan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - A Filippi
- INFN, Sezione di Torino, 10125 Torino, Italy
| | - T A Forest
- Idaho State University, Pocatello, Idaho 83209, USA
| | - A Fradi
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - M Garçon
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - G Gavalian
- Old Dominion University, Norfolk, Virginia 23529, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N Gevorgyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - G P Gilfoyle
- University of Richmond, Richmond, Virginia 23173, USA
| | - K L Giovanetti
- James Madison University, Harrisonburg, Virginia 22807, USA
| | - E Golovatch
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - R W Gothe
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - K A Griffioen
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - N Harrison
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - T B Hayward
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - D Heddle
- Christopher Newport University, Newport News, Virginia 23606, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Hicks
- Ohio University, Athens, Ohio 45701, USA
| | - M Holtrop
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - Y Ilieva
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D G Ireland
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - E L Isupov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - H S Jo
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - S Johnston
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - D Keller
- Ohio University, Athens, Ohio 45701, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - M Khachatryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Khanal
- Florida International University, Miami, Florida 33199, USA
| | - M Khandaker
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - C W Kim
- The George Washington University, Washington, DC 20052, USA
| | - W Kim
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - F J Klein
- Catholic University of America, Washington, DC 20064, USA
| | - V Kubarovsky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S E Kuhn
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - L Lanza
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
| | - M L Kabir
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - P Lenisa
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - K Livingston
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | | | - D Marchand
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - N Markov
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - M Mayer
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - B McKinnon
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - Z E Meziani
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Mineeva
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - M Mirazita
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | | | - C Munoz Camacho
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - P Nadel-Turonski
- Catholic University of America, Washington, DC 20064, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Niccolai
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - A I Ostrovidov
- Florida State University, Tallahassee, Florida 32306, USA
| | | | - R Paremuzyan
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E Pasyuk
- Arizona State University, Tempe, Arizona 85287-1504, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - O Pogorelko
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - J Poudel
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - Y Prok
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - M Ripani
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - D Riser
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - A Rizzo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Universita' di Roma Tor Vergata, 00133 Rome, Italy
| | - G Rosner
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - P Rossi
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Sabatié
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - C Salgado
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - R A Schumacher
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y G Sharabian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Iu Skorodumina
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D Sokhan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Soto
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - S Strauch
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Taiuti
- Universitá di Genova, 16146 Genova, Italy
| | - J A Tan
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - N Tyler
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Ungaro
- University of Connecticut, Storrs, Connecticut 06269, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Voskanyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - R Wang
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - D P Watts
- University of York, York YO10 5DD, United Kingdom
| | - X Wei
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - L B Weinstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - M H Wood
- Canisius College, Buffalo, New York, USA
| | - N Zachariou
- University of York, York YO10 5DD, United Kingdom
| | - J Zhang
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - Z W Zhao
- Duke University, Durham, North Carolina 27708-0305, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| |
Collapse
|
26
|
Irfan T, Turkes F, Asare B, Mohammed K, Osin P, Nerurkar A, Smith I, Parton M, Johnston S, Turner N, Okines A. Clinical Outcomes in Triple-negative Lobular Breast Cancer: a Single-institution Experience. Clin Oncol (R Coll Radiol) 2019. [DOI: 10.1016/j.clon.2019.03.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Roy P, Park S, Crede V, Anisovich AV, Klempt E, Nikonov VA, Sarantsev AV, Wei NC, Huang F, Nakayama K, Adhikari KP, Adhikari S, Angelini G, Avakian H, Barion L, Battaglieri M, Bedlinskiy I, Biselli AS, Boiarinov S, Briscoe WJ, Brock J, Brooks WK, Burkert VD, Cao F, Carlin C, Carman DS, Celentano A, Chatagnon P, Chetry T, Ciullo G, Cole PL, Contalbrigo M, Cortes O, D'Angelo A, Dashyan N, De Vita R, De Sanctis E, Deur A, Diehl S, Djalali C, Dugger M, Dupre R, Duran B, Egiyan H, Ehrhart M, El Alaoui A, El Fassi L, Eugenio P, Fegan S, Filippi A, Fradi A, Gilfoyle GP, Girod FX, Golovatch E, Gothe RW, Griffioen KA, Guidal M, Guo L, Hafidi K, Hanretty C, Harrison N, Hattawy M, Hayward TB, Heddle D, Hicks K, Holtrop M, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Jenkins D, Jo HS, Johnston S, Joosten S, Kabir ML, Keith CD, Keller D, Khachatryan G, Khachatryan M, Khanal A, Khandaker M, Kim A, Kim W, Klein FJ, Kubarovsky V, Kuleshov SV, Kunkel MC, Lanza L, Lenisa P, Livingston K, MacGregor IJD, Marchand D, McKinnon B, Meekins DG, Meyer CA, Mineeva T, Mokeev V, Montgomery RA, Movsisyan A, Munoz Camacho C, Nadel-Turonski P, Niccolai S, Niculescu G, Osipenko M, Ostrovidov AI, Paolone M, Pappalardo LL, Paremuzyan R, Pasyuk E, Payette D, Phelps W, Pierce J, Pogorelko O, Prok Y, Protopopescu D, Raue BA, Ripani M, Riser D, Ritchie BG, Rizzo A, Rosner G, Sabatié F, Salgado C, Schumacher RA, Seely ML, Sharabian YG, Shrestha U, Skorodumina I, Sokhan D, Soto O, Sparveris N, Strakovsky II, Strauch S, Taiuti M, Tan JA, Torayev B, Tyler N, Ungaro M, Voskanyan H, Voutier E, Walford NK, Wang R, Watts DP, Wei X, Wood MH, Zachariou N, Zhang J, Zhao ZW. First Measurements of the Double-Polarization Observables F, P, and H in ω Photoproduction off Transversely Polarized Protons in the N^{*} Resonance Region. Phys Rev Lett 2019; 122:162301. [PMID: 31075002 DOI: 10.1103/physrevlett.122.162301] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 03/12/2019] [Indexed: 06/09/2023]
Abstract
First measurements of double-polarization observables in ω photoproduction off the proton are presented using transverse target polarization and data from the CEBAF Large Acceptance Spectrometer (CLAS) FROST experiment at Jefferson Lab. The beam-target asymmetry F has been measured using circularly polarized, tagged photons in the energy range 1200-2700 MeV, and the beam-target asymmetries H and P have been measured using linearly polarized, tagged photons in the energy range 1200-2000 MeV. These measurements significantly increase the database on polarization observables. The results are included in two partial-wave analyses and reveal significant contributions from several nucleon (N^{*}) resonances. In particular, contributions from new N^{*} resonances listed in the Review of Particle Properties are observed, which aid in reaching the goal of mapping out the nucleon resonance spectrum.
Collapse
Affiliation(s)
- P Roy
- Florida State University, Tallahassee, Florida 32306, USA
| | - S Park
- Florida State University, Tallahassee, Florida 32306, USA
| | - V Crede
- Florida State University, Tallahassee, Florida 32306, USA
| | - A V Anisovich
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- NRC "Kurchatov Institute," PNPI, 188300, Gatchina, Russia
| | - E Klempt
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - V A Nikonov
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- NRC "Kurchatov Institute," PNPI, 188300, Gatchina, Russia
| | - A V Sarantsev
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- NRC "Kurchatov Institute," PNPI, 188300, Gatchina, Russia
| | - N C Wei
- Zhengzhou University, Zhengzhou, Henan 450001, China
- School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing 100049, China
| | - F Huang
- School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing 100049, China
| | - K Nakayama
- University of Georgia, Athens, Georgia 30602, USA
| | - K P Adhikari
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Adhikari
- Florida International University, Miami, Florida 33199, USA
| | - G Angelini
- The George Washington University, Washington, DC 20052, USA
| | - H Avakian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - L Barion
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | | | - I Bedlinskiy
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - A S Biselli
- Fairfield University, Fairfield, Connecticut 06824, USA
| | - S Boiarinov
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W J Briscoe
- The George Washington University, Washington, DC 20052, USA
| | - J Brock
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W K Brooks
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - V D Burkert
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Cao
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Carlin
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D S Carman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Celentano
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - P Chatagnon
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - G Ciullo
- Università di Ferrara, 44121 Ferrara, Italy
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - P L Cole
- Idaho State University, Pocatello, Idaho 83209, USA
- Lamar University, 4400 MLK Blvd, P.O. Box 10009, Beaumont, Texas 77710, USA
| | | | - O Cortes
- The George Washington University, Washington, DC 20052, USA
| | - A D'Angelo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Università di Roma Tor Vergata, 00133 Rome, Italy
| | - N Dashyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - R De Vita
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - E De Sanctis
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - A Deur
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Diehl
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Djalali
- Ohio University, Athens, Ohio 45701, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Dugger
- Arizona State University, Tempe, Arizona 85287-1504, USA
| | - R Dupre
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - H Egiyan
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Ehrhart
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - A El Alaoui
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - L El Fassi
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - P Eugenio
- Florida State University, Tallahassee, Florida 32306, USA
| | - S Fegan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - A Filippi
- INFN, Sezione di Torino, 10125 Torino, Italy
| | - A Fradi
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - G P Gilfoyle
- University of Richmond, Richmond, Virginia 23173, USA
| | - F X Girod
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - E Golovatch
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - R W Gothe
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - K A Griffioen
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - M Guidal
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - L Guo
- Florida International University, Miami, Florida 33199, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Hafidi
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - C Hanretty
- Florida State University, Tallahassee, Florida 32306, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N Harrison
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Hattawy
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - T B Hayward
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - D Heddle
- Christopher Newport University, Newport News, Virginia 23606, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Hicks
- Ohio University, Athens, Ohio 45701, USA
| | - M Holtrop
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - Y Ilieva
- The George Washington University, Washington, DC 20052, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D G Ireland
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - B S Ishkhanov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - E L Isupov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - D Jenkins
- Virginia Tech, Blacksburg, Virginia 24061-0435, USA
| | - H S Jo
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - S Johnston
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - S Joosten
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - M L Kabir
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - C D Keith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Keller
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - M Khachatryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Khanal
- Florida International University, Miami, Florida 33199, USA
| | - M Khandaker
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - A Kim
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - W Kim
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - F J Klein
- Catholic University of America, Washington, D.C. 20064, USA
| | - V Kubarovsky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S V Kuleshov
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - M C Kunkel
- Institut für Kernphysik, 52425 Jülich, Germany
| | - L Lanza
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
| | - P Lenisa
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - K Livingston
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | | | - D Marchand
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - B McKinnon
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - D G Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C A Meyer
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - T Mineeva
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - V Mokeev
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - A Movsisyan
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - C Munoz Camacho
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Niccolai
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - G Niculescu
- James Madison University, Harrisonburg, Virginia 22807, USA
| | - M Osipenko
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - A I Ostrovidov
- Florida State University, Tallahassee, Florida 32306, USA
| | - M Paolone
- University of South Carolina, Columbia, South Carolina 29208, USA
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | | | - R Paremuzyan
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E Pasyuk
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Payette
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Phelps
- The George Washington University, Washington, DC 20052, USA
| | - J Pierce
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - O Pogorelko
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - Y Prok
- Christopher Newport University, Newport News, Virginia 23606, USA
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - B A Raue
- Florida International University, Miami, Florida 33199, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Ripani
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - D Riser
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - B G Ritchie
- Arizona State University, Tempe, Arizona 85287-1504, USA
| | - A Rizzo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Università di Roma Tor Vergata, 00133 Rome, Italy
| | - G Rosner
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - F Sabatié
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - C Salgado
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - R A Schumacher
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - M L Seely
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y G Sharabian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - U Shrestha
- Ohio University, Athens, Ohio 45701, USA
| | - Iu Skorodumina
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - D Sokhan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Soto
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - I I Strakovsky
- The George Washington University, Washington, DC 20052, USA
| | - S Strauch
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Taiuti
- Università di Genova, 16146 Genova, Italy
| | - J A Tan
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - B Torayev
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - N Tyler
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Ungaro
- University of Connecticut, Storrs, Connecticut 06269, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Voskanyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E Voutier
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - N K Walford
- Catholic University of America, Washington, D.C. 20064, USA
| | - R Wang
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, F-91406 Orsay, France
| | - D P Watts
- University of York, York YO10, United Kingdom
| | - X Wei
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M H Wood
- Canisius College, Buffalo, New York 14208, USA
| | - N Zachariou
- The George Washington University, Washington, DC 20052, USA
- University of York, York YO10, United Kingdom
| | - J Zhang
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - Z W Zhao
- Duke University, Durham, North Carolina 27708-0305, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| |
Collapse
|
28
|
Polley MYC, Dickler MN, Johnston S, Goetz MP, de la Haba J, Loibl S, Mehta RS, Bergh J, Roberston J, Barlow W, Liu H, Tenner K, Martin M. Abstract P2-07-05: A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-07-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Endocrine based therapy is an effective strategy to manage hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). However, nearly all patients exhibit/develop either de novo or acquired resistance. While prognostic biomarkers of endocrine responsiveness are well established for the adjuvant treatment in ER+ breast cancer, less is known regarding prognostic and predictive biomarkers of response in the first line ABC setting. We sought to develop a clinical calculator based on clinical criteria for predicting progression-free survival (PFS) and overall survival (OS) of women with HR+/HER2- ABC who will be receiving endocrine monotherapy as first-line treatment for ABC.
Methods: The development of the clinical calculator will be based on data from modern clinical trials in women with HR+/HER2- ABC. The studies to be included in the final analyses are given in Table 1. The control arm data from trials1-6 will form the training dataset (N = 1,223) and be used to construct the clinical prediction models. Variables considered include age, race, ECOG status, disease measurability, body mass index, disease-free interval, number of metastatic sites, locations of metastatic sites, prior endocrine therapy, and prior chemotherapy. Missing values will be imputed using single imputation with all variables included in the imputation model. For continuous variables, restricted cubic splines will be used to determine if non-linear effects may be more appropriate. The Lasso regression will be used as a variable selection technique to reduce the dimensionality of covariates; initially all pairwise interactions will be included in the model. Following Lasso regression, the multivariable Cox proportional hazards models will be constructed for PFS and OS including only variables retained in Lasso. The final model will be internally validated for discrimination and calibration using 10-fold cross-validation. External validation will be performed using control arm data from EGF 30008 (N = 536).
Results: To date, control arm data from four trials (trials 1-4) have been received. The preliminary results presented here are based on pooled data from C40503 and LEA, for which data elements have been harmonized. Models for predicting PFS and OS have good calibration and are associated with bias-corrected C-indices of 0.61 and 0.65, respectively. These models will be updated using pooled data from trials 1-6.
Conclusions: Our preliminary data demonstrate that clinical calculators based on baseline clinical factors can provide accurate prediction of PFS and OS in patients with HR+/HER2- ABC treated with first-line ET. If validated, these tools may be used for risk stratification in future clinical trials and to identify patients who may require more or less aggressive therapy.
Table 1:Studies to be includedTrial NumberTrial NameTrial PISample Size in Control Arm1C40503Maura Dickler152 (letrozole)2LEAMiguel Martin179 (letrozole)3FACTJonas Bergh188 (anastrozole)4FALCONJohn Robertson194 (anastrozole)5S0226Rita Mehta345 (anastrozole)6MONARCH 3Matthew Goetz165 (nonsteroidal AI)7EGF 30008Stephen Johnston536 (letrozole)
Citation Format: Polley M-YC, Dickler MN, Johnston S, Goetz MP, de la Haba J, Loibl S, Mehta RS, Bergh J, Roberston J, Barlow W, Liu H, Tenner K, Martin M. A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-07-05.
Collapse
Affiliation(s)
- M-YC Polley
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - MN Dickler
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - S Johnston
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - MP Goetz
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - J de la Haba
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - S Loibl
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - RS Mehta
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - J Bergh
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - J Roberston
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - W Barlow
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - H Liu
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - K Tenner
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| | - M Martin
- Mayo Clinic, Rochester, MN; Eli Lilly, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom; GEICAM, Madrid, Spain; German Breast Group (GBG), Neu-Isenburg, Germany; University of California, Irvine, Orange, CA; Karolinska Institute, Stockholm, Sweden; University of Nottingham, Nottingham, United Kingdom; Southwest Oncology Group (SWOG), Seattle, WA; Gregorio Marañón University Hospital, Madrid, Spain
| |
Collapse
|
29
|
Robertson JFR, Di Leo A, Johnston S, Chia S, Bliss J, Bradbury I, Campbell C. Abstract P4-13-13: Meta-analyses of visceral versus non-visceral metastases treated by AI & SERD agents as 2nd line endocrine therapy (ET) for HR+ breast cancer (BC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-13-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
There is a prevailing belief that ET for HR+ advanced BC is not as effective in patients with visceral metastases (VM) compared to non-visceral metastases (nVM), particularly with later lines of ET. Recently fulvestrant 500mg (Ful 500), has been reported to have greater efficacy in nVM compared to i) VM treated by Ful 500 but also compared to ii) nVM treated by Ful 250 (2nd line) and iii) nVM treated by aromatase inhibitor (AI), anastrozole (1st Line) – implying both site and agent related efficacy. Absence of significant overall survival (OS) difference in PALOMA 3 (2nd line) has increased the debate regarding when to add CDK 4/6is to ET, especially given the OS advantage for Ful 500 monotherapy in the 1st & 2nd line settings.
Patients & Methods: Anonymised, individual patient level data was obtained from randomised controlled trials (RCTs) involving AI & SERD used as mono-theraphy in 2nd or 3rd Line setting in known HR+ BC. All the trials were Phase 3 double-blind, placebo RCTs. All were rigorously assessed for clinical benefit (CB), progression free survival (PFS), duration of CB (DoCB) and OS. Details of the studies, types of ET and patient numbers are shown in the Table.
Results: Outcome data is presented for each study and then summarised under AI, SERD (Ful 250 or 500) and 'all Ets combined'. Odds ratios (Ors) & hazard ratios (HRs) for VM versus nVM by endocrine agents are shown in the Table.
AgentStudyTotal Pats.HR+ Pats.CBRPFSOSDoCBAI(n)(n)OR (95%Cis)HR (95%Cis)HR (95%Cis)HR (95%Cis)Exe00202301831.181.441.271.50Exe00211931681.151.951.832.12AnaEFECT3403360.941.521.201.10AnaSOFEA2492491.291.181.051.41subtotal7636871.11 (0.84-1.48)1.47*** (1.22-1.79)1.21* (1.01-1.45)1.43** (1.10-1.86)SERDFul 25000202191601.791.701.401.23Ful 25000212041771.281.811.322.06Ful 250EFECT3513450.791.401.311.03Ful 250SOFEA2312310.701.171.242.22Ful 250CONFIRM1521521.131.071.510.84Subtotal9268341.05 (0.75-1.45)1.39*** (1.16-1.67)1.34*** (1.14-1.57)1.36 (0.93-1.98)SERDFul 500CONFIRM1441442.24 (1.12-4.48)1.30 (0.90-1.87)1.33 (1.14-1.57)0.97 (0.55-1.66)All ETsTotal183316651.13 (0.92-1.39)1.42*** (1.26-1.59)1.28*** (1.14-1.44)1.35** (1.09-1.66)
[Pats=Patients; (n)=number; CBR-Clinical Benefit Rate; p-values p<0.05*, p<0.01**, p<0.001***]
Median PFS (months) for nVM for AI, SERD250, SERD500 & ‘all Ets combined’ were 5.4, 5.5, 11.0 & 5.5 respectively: for VM they were 2.9, 3.5, 5.5 & 3.2 respectively.
Median OS (months) for nVM for AI, SERD250, SERD500 & ‘all Ets combined’ was 24.2, 26.0, 35.4 & 25.4 respectively: for VM the figures were 22.8, 20.8, 26.4 & 22.0 respectively.Conclusions:1) In the 2nd line HR+ setting AI & Ful 250 both significantly increased PFS & OS in nVM versus VM. Longer PFS appears due to longer duration of control (DoCB) than increasing the number of patients responding (CBR).
2) Median OS for nVM ranged from 24 – 35 months versus 20.8-26.4 months for VM: for the majority of patients the 2nd line ET setting is not ‘immediately life threating’ and ET is therefore an option to consider.
3) These data on site of disease (nVM vs VM) contribute to the selection of which patients should receive endocrine mono- and which endocrine combination therapy (ie plus mTORi or CDK4/6i) in the second line setting.
Citation Format: Robertson JFR, Di Leo A, Johnston S, Chia S, Bliss J, Bradbury I, Campbell C. Meta-analyses of visceral versus non-visceral metastases treated by AI & SERD agents as 2nd line endocrine therapy (ET) for HR+ breast cancer (BC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-13-13.
Collapse
Affiliation(s)
- JFR Robertson
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| | - A Di Leo
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| | - S Johnston
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| | - S Chia
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| | - J Bliss
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| | - I Bradbury
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| | - C Campbell
- University of Nottingham, Nottingham, Nottinghamshire, United Kingdom; Sandra Pitigliani Medical Oncology Unit, Hospital of Prato, Prato, Italy; Royal Marsden NHS Foundation Trust, London, United Kingdom; British Columbia Cancer Agency, Vancouver, Canada; The Institute of Cancer Research, London, United Kingdom; Frontier Science, Kincraig, Inverness-shire, United Kingdom
| |
Collapse
|
30
|
Goetz MP, Johnston S, Martin M, Tokunaga E, Park IH, Huober J, Toi M, Price GL, Boye M, Li L, Forrester T, Gainford C, Gable J, Carter GC, Sood A, DiLeo A. Abstract P6-16-01: Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2- advanced breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-16-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In the MONARCH 3 trial, abemaciclib plus an aromatase inhibitor (AI) significantly improved progression free survival and overall response rate with a generally tolerable safety profile compared to placebo plus AI. Here we report patient-reported outcomes (PRO) including health-related quality of life (Qol), functioning, and symptoms.
Methods: MONARCH 3 was a double-blind, randomized phase III study of abemaciclib or placebo plus an AI in 493 post-menopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer with no prior systemic therapy in the advanced setting. Two European Organization for Research and Treatment of Cancer (EORTC) questionnaires were included: Quality of Life Questionnaire (QLQ)-Core 30 (C30) and the EORTC QLQ-Breast 23 (BR23) that were assessed at baseline, every 2 cycles through cycle 19, then every 3 cycles until treatment discontinuation, and at short-term follow up. Higher scores on functional and health status/QoL outcomes indicate higher/better levels of functioning or health; conversely higher scores on symptom outcomes indicate higher/worse levels of symptom burden. Between-arm comparisons of change from baseline were conducted using mixed model methods. Statistical significance was set at 0.05 and clinical meaningfulness was set at ≥10 points on a 0-100 scale1.
Results: PRO completion rates were >91% through cycle 19; duration of treatment was longer for abemaciclib plus AI patients (median number of cycles 19 vs.15). Compared to the placebo arm, diarrhea PRO scores in the abemaciclib arm showed a clinically (18.68 points) and statistically significant (p<0.001) increase/worsening. By-cycle analysis showed group mean diarrhea scores returned to near-baseline levels post-therapy. Other symptom PROs showed statistically significant (<0.05) but not clinically meaningful differences; fatigue (4.96; p=0.004), systemic therapy side effects (4.48, p<0.001), appetite loss (4.03; p=0.034), and nausea/vomiting (2.77; p=0.013). These results were consistent with the investigator-reported treatment emergent adverse events (TEAEs). Several non-symptom results were also statistically significant but not clinically meaningful including global health/health status (-4.36; p=0.003), role function (-4.25; p=0.025), social function (-3.41, p=0.047), and body image (-5.11, p=0.009). No statistically significant between-treatment differences were observed for physical, emotional, and cognitive functioning or for symptoms of pain, dyspnea, insomnia, constipation, or financial difficulties.
Conclusions: The addition of abemaciclib to an AI resulted in clinically and statistically significant changes in diarrhea without clinically meaningful differences in other symptom scores. Increased GI-related symptoms were consistent with the manageable, reversible AE profile; the highest symptom burden was reported during early visits. No clinically meaningful differences in global health status or functional scores were observed.
ClinicalTrials.gov: NCT02246621
Reference:
1. Osoba D et al. J Clin Oncol 2002;20(14):3106-13.
Citation Format: Goetz MP, Johnston S, Martin M, Tokunaga E, Park IH, Huober J, Toi M, Price GL, Boye M, Li L, Forrester T, Gainford C, Gable J, Carter GC, Sood A, DiLeo A. Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2- advanced breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-16-01.
Collapse
Affiliation(s)
- MP Goetz
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - S Johnston
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - M Martin
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - E Tokunaga
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - IH Park
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - J Huober
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - M Toi
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - GL Price
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - M Boye
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - L Li
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - T Forrester
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - C Gainford
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - J Gable
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - GC Carter
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - A Sood
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| | - A DiLeo
- Mayo Clinic, Rochester, MN; Royal Marsden NHS Foundation Trust, London, United Kingdom; Instituto de Investigación Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Cancer Center, Goyangsi, Korea; University of Ulm, Ulm, Germany; Kyoto University Hospital, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Services India Pvt. Ltd., Bangalore, India; Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy
| |
Collapse
|
31
|
Turner N, Garcia-Murillas I, Chopra N, Comino-Mendez I, Beaney M, Tovey H, Cutts R, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh G, Johnston S, Ring A, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith I. Abstract P4-01-01: Molecular residual disease detection with circulating tumor DNA analysis predicts relapse in patients with early stage breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-01-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Detection of circulating tumor DNA (ctDNA) after treatment of early stage breast cancer may identify molecular residual disease. In a prior proof-of-principle study we demonstrated that detection of ctDNA predicted relapse with high accuracy (Garcia-Murillas et al Science Trans Med 2015). We conducted an independent, prospective, multi-centre validation study.
Methods. In this validation study, a cohort of 170 early stage breast cancer patients were recruited from five hospitals into two prospective sample collection studies. Patients were scheduled to receive standard chemotherapy, surgery +/- radiotherapy, adjuvant endocrine therapy and HER2 antibodies as appropriate. Plasma samples were collected for ctDNA analysis at baseline, post-surgery, three monthly for the first year of follow-up, and six monthly thereafter and shipped to a central lab for processing. Using previously established criteria, tumor was sequenced to identify somatic mutations that were tracked by digital PCR in DNA extracted from 4mls of plasma at all available time points. Buffy coat DNA was analysed at all time-points to control for clonal haematopoesis of indeterminate potential (CHIP) detection. The primary endpoint was to compare invasive disease free survival between patients with and without detection of ctDNA after treatment. A combined analysis of this validation study, and the prior proof-of-principle study, was also conducted to analyse secondary endpoints.
Results. After tumor sequencing, 101 patients from the validation study had at least one mutation to track. At median 35.5 months follow-up, ctDNA was detected in plasma of 15.8% (16/101) patients. Detection of ctDNA strongly predicted relapse, hazard ratio 24.5 (95% CI 6.5 to 93.2, P<0.001 time-dependent Cox model), and was predictive of relapse in all tumor subtypes.
In the combined analysis (N=144), lead-time between ctDNA detection and relapse was 10.7 months (95% CI 7.7-17.0). Six patients had a clinical relapse that was not detected by ctDNA prior to relapse. These patients had a distinct pattern of oligo-metastatic relapse, 3 patients with brain-only metastases (P=0.0068), 1 ovarian oligo-metastasis and 2 local disease recurrence. The level of ctDNA in baseline plasma, prior to treatment, was associated with tumor subtype, highest in triple negative breast cancer (P=0.0036).
Conclusion. Detection of ctDNA after treatment is associated with a high risk of future relapse in early-stage breast cancer. Prospective studies are required to assess the potential of molecular residual disease detection to guide adjuvant therapy.
Citation Format: Turner N, Garcia-Murillas I, Chopra N, Comino-Mendez I, Beaney M, Tovey H, Cutts R, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh G, Johnston S, Ring A, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith I. Molecular residual disease detection with circulating tumor DNA analysis predicts relapse in patients with early stage breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-01-01.
Collapse
Affiliation(s)
- N Turner
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - I Garcia-Murillas
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - N Chopra
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - I Comino-Mendez
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - M Beaney
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - H Tovey
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - R Cutts
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - C Swift
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - D Kriplani
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - M Afentakis
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - S Hrebien
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - G Walsh
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - S Johnston
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - A Ring
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - S Russell
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - A Evans
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - A Skene
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - D Wheatley
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - M Dowsett
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| | - I Smith
- The Institute of Cancer Research, Lomdon, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Hinchingbrooke Hospital, Hungtindon, United Kingdom; Poole General Hospital, Poole, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom
| |
Collapse
|
32
|
Dowsett M, Jacobs S, Johnston S, Bliss J, Wheatley D, Holcombe C, Stein R, McIntosh S, Barry P, Dolling D, Snowdon C, Perry S, Batten L, Dodson A, Martins V, Modi A, Cornman C, Puhalla S, Wolmark N, Julian T, Pogue-Geile K, Robidoux A, Provencher L, Boileau JF, Shalaby I, Thirlwell M, Fisher K, Huang Bartlett C, Koehler M, Osborne K, Rimawi M. Abstract GS3-02: PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs3-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: CDK4/6 inhibitors, such as palbociclib, are used to treat ER+ metastatic breast cancer in combination with endocrine therapy with trials ongoing in patients with primary disease. No biomarkers exist to identify those who do/do not benefit from added CDK4/6 inhibition. PALLET is an investigator-initiated/led phase II randomized trial collaboration between UK and NSABP investigators evaluating the biological and clinical effects of palbociclib with letrozole combination as neoadjuvant therapy.
Methods: Postmenopausal women with ER+ primary breast cancer and tumors >2.0cm (ultrasound) were randomized to one of 4 treatment groups (3:2:2:2 ratio): Group A: letrozole (2.5mg/d) for 14 weeks; Group B: letrozole for 2 weeks followed by letrozole + palbociclib to 14 weeks; Group C: palbociclib for 2 weeks followed by letrozole + palbociclib to 14 weeks; Group D: letrozole + palbociclib for 14 weeks. Palbociclib was given 125mg/d PO on a 21 days on, 7 days off schedule. Post-14 week treatment was at the discretion of the treating clinician including letrozole until surgery. Core-cut biopsies were taken at baseline, 2 weeks and 14 weeks. Co-primary endpoints for letrozole alone vs palbociclib groups (Group A vs Groups B+C+D) were: (i) change in Ki67 (IHC) between baseline and 14 weeks (log-fold change, Mann-Whitney test); (ii) clinical response (ultrasound) after 14 weeks (4 group, ordinal, Mann-Whitney test). Complete cell-cycle arrest (CCCA) (Ki67≤2.7%) was analyzed using a logistic regression model adjusting for recruitment region. Pre-specified exploratory biomarkers included c-PARP (apoptosis).
Results: 307 patients were recruited between 27 Feb 2015 and 08 Mar 2018; 103 were randomized to letrozole alone and 204 to letrozole + palbociclib. 279 (90.9%) patients were evaluable for 14 week clinical response. Clinical response was not significantly different between letrozole vs letrozole + palbociclib groups [(p=0.20; CR+PR 49.5% (46/93) vs 54.3% (101/186) and PD 5.4% (5/93) vs 3.2% (6/186)] nor was the small proportion of patients with pathological CR (1/87, 1.1% vs 6/180, 3.3%; p=0.43). 190 (61.9%) patients were evaluable for 14 week change in Ki67. The median log-fold change in Ki67 was greater with letrozole + palbociclib vs letrozole alone (-4.1 vs -2.2; p<0.001) corresponding to a geometric mean change of -97.4% vs -88.5%. Similarly, a greater proportion of patients who received letrozole + palbociclib achieved CCCA (90% vs 59%, p<0.001). 146 (47.6%) patients were evaluable for c-PARP and the log-fold change (suppression) was greater with letrozole + palbociclib vs letrozole alone (-0.80 vs -0.42; p=0.003) corresponding to a geometric mean change of -56.8% vs -31.4%. Other biomarkers of response / resistance are being evaluated. A higher proportion of patients had a grade ≥3 toxicity on letrozole + palbociclib than letrozole alone (49.8% vs 17.0%; p<0.001) mainly due to asymptomatic neutropenia.
Conclusion: Adding palbociclib to letrozole markedly enhanced the suppression of malignant cell proliferation as assessed by Ki67 but did not substantially increase the clinical response of primary ER+ breast cancer over a 14-week period. Concurrent reductions in cell death may have reduced the speed of tumor shrinkage.
Citation Format: Dowsett M, Jacobs S, Johnston S, Bliss J, Wheatley D, Holcombe C, Stein R, McIntosh S, Barry P, Dolling D, Snowdon C, Perry S, Batten L, Dodson A, Martins V, Modi A, Cornman C, Puhalla S, Wolmark N, Julian T, Pogue-Geile K, Robidoux A, Provencher L, Boileau JF, Shalaby I, Thirlwell M, Fisher K, Huang Bartlett C, Koehler M, Osborne K, Rimawi M. PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS3-02.
Collapse
Affiliation(s)
- M Dowsett
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - S Jacobs
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - S Johnston
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - J Bliss
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - D Wheatley
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - C Holcombe
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - R Stein
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - S McIntosh
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - P Barry
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - D Dolling
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - C Snowdon
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - S Perry
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - L Batten
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - A Dodson
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - V Martins
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - A Modi
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - C Cornman
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - S Puhalla
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - N Wolmark
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - T Julian
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - K Pogue-Geile
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - A Robidoux
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - L Provencher
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - JF Boileau
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - I Shalaby
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - M Thirlwell
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - K Fisher
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - C Huang Bartlett
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - M Koehler
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - K Osborne
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| | - M Rimawi
- The Institute of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada
| |
Collapse
|
33
|
Schlappa J, Kumar U, Zhou KJ, Singh S, Mourigal M, Strocov VN, Revcolevschi A, Patthey L, Rønnow HM, Johnston S, Schmitt T. Probing multi-spinon excitations outside of the two-spinon continuum in the antiferromagnetic spin chain cuprate Sr 2CuO 3. Nat Commun 2018; 9:5394. [PMID: 30568161 PMCID: PMC6300594 DOI: 10.1038/s41467-018-07838-y] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2018] [Accepted: 11/26/2018] [Indexed: 11/09/2022] Open
Abstract
One-dimensional (1D) magnetic insulators have attracted significant interest as a platform for studying quasiparticle fractionalization, quantum criticality, and emergent phenomena. The spin-1/2 Heisenberg chain with antiferromagnetic nearest neighbour interactions is an important reference system; its elementary magnetic excitations are spin-1/2 quasiparticles called spinons that are created in even numbers. However, while the excitation continuum associated with two-spinon states is routinely observed, the study of four-spinon and higher multi-spinon states is an open area of research. Here we show that four-spinon excitations can be accessed directly in Sr2CuO3 using resonant inelastic x-ray scattering (RIXS) in a region of phase space clearly separated from the two-spinon continuum. Our finding is made possible by the fundamental differences in the correlation function probed by RIXS in comparison to other probes. This advance holds promise as a tool in the search for novel quantum states and quantum spin liquids.
Collapse
Affiliation(s)
- J Schlappa
- European X-Ray Free-Electron Laser Facility GmbH, Holzkoppel 4, 22869, Schenefeld, Germany.
- Photon Science Division, Paul Scherrer Institut, 5232, Villigen PSI, Switzerland.
| | - U Kumar
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, TN, 37996, USA
| | - K J Zhou
- Photon Science Division, Paul Scherrer Institut, 5232, Villigen PSI, Switzerland
- Diamond Light Source, Harwell Science and Innovation Campus, Didcot, Oxfordshire, OX11 0DE, UK
| | - S Singh
- Department of Physics, Indian Institute of Science Education and Research, Dr. Homi Bhabha Road, Pune, 411008, India
| | - M Mourigal
- École Polytechnique Fédérale de Lausanne, 1015, Lausanne, Switzerland
- School of Physics, Georgia Institute of Technology, Atlanta, GA, 30332, USA
| | - V N Strocov
- Photon Science Division, Paul Scherrer Institut, 5232, Villigen PSI, Switzerland
| | - A Revcolevschi
- Institut de Chimie Moléculaire et des Matériaux d'Orsay, Université Paris-Sud 11, UMR 8182, 91405, Orsay, France
| | - L Patthey
- Photon Science Division, Paul Scherrer Institut, 5232, Villigen PSI, Switzerland
| | - H M Rønnow
- École Polytechnique Fédérale de Lausanne, 1015, Lausanne, Switzerland
| | - S Johnston
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, TN, 37996, USA.
| | - T Schmitt
- Photon Science Division, Paul Scherrer Institut, 5232, Villigen PSI, Switzerland.
| |
Collapse
|
34
|
Tang SSK, Rapisarda F, Nerurkar A, Osin P, MacNeill F, Smith I, Johnston S, Ross G, Mohammed K, Gui GPH. Complete excision with narrow margins provides equivalent local control to wider excision in breast conservation for invasive cancer. BJS Open 2018; 3:161-168. [PMID: 30957062 PMCID: PMC6433318 DOI: 10.1002/bjs5.50121] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Accepted: 10/22/2018] [Indexed: 11/07/2022] Open
Abstract
Background Society of Surgical Oncology and American Society for Radiation Oncology guidelines define clear margins in breast-conserving therapy (BCT) as 'no ink on tumour', in contrast to the attainment of margins of at least 1 mm widely practised in the UK. The primary aim of this study was to explore clinical, surgical and tumour-related factors associated with local recurrence after BCT, with a secondary aim of assessing the impact of margin re-excision on the risk of local recurrence. Methods Patient demographics, surgical details, tumour characteristics and local recurrence were recorded for consecutive women with BCT undergoing surgery between January 1997 and January 2007. Margins were defined as clear (greater than 1 mm), close (less than 1 mm but no ink on tumour), reaches (ink on tumour) and clear after re-excision. Results A total of 1045 women of median age 54 (range 18-86) years were studied. Median follow-up was 89 (range 4-196) months. Local recurrence occurred in 52 patients (5·0 per cent). Ink on tumour was associated with local recurrence (hazard ratio (HR) 4·86, 95 per cent c.i. 1·49 to 15·79; P = 0·009). Risk of local recurrence was the same for close and clear margins (HR 1·03, 0·40 to 2·62; P = 0·954). In women with involved margins, re-excision was still associated with an increased local recurrence risk (HR 2·50, 1·32 to 4·72; P = 0·005). Oestrogen receptor negativity increased risk (HR 2·28, 1·28 to 4·06; P = 0·005). Conclusion Adequately excised margins, even when under 1 mm, provide equivalent outcomes to wider margins in BCT. Achieving complete excision at primary surgery achieves the lowest rates of local recurrence.
Collapse
Affiliation(s)
- S S K Tang
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - F Rapisarda
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - A Nerurkar
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - P Osin
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - F MacNeill
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - I Smith
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - S Johnston
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - G Ross
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - K Mohammed
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| | - G P H Gui
- Academic Breast Unit Royal Marsden Hospital Fulham Road, London SW3 6JJ UK
| |
Collapse
|
35
|
Meyers D, Nakatsukasa K, Mu S, Hao L, Yang J, Cao Y, Fabbris G, Miao H, Pelliciari J, McNally D, Dantz M, Paris E, Karapetrova E, Choi Y, Haskel D, Shafer P, Arenholz E, Schmitt T, Berlijn T, Johnston S, Liu J, Dean MPM. Decoupling Carrier Concentration and Electron-Phonon Coupling in Oxide Heterostructures Observed with Resonant Inelastic X-Ray Scattering. Phys Rev Lett 2018; 121:236802. [PMID: 30576191 DOI: 10.1103/physrevlett.121.236802] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Revised: 10/15/2018] [Indexed: 06/09/2023]
Abstract
We report the observation of multiple phonon satellite features in ultrathin superlattices of the form nSrIrO_{3}/mSrTiO_{3} using resonant inelastic x-ray scattering (RIXS). As the values of n and m vary, the energy loss spectra show a systematic evolution in the relative intensity of the phonon satellites. Using a closed-form solution for the RIXS cross section, we extract the variation in the electron-phonon coupling strength as a function of n and m. Combined with the negligible carrier doping into the SrTiO_{3} layers, these results indicate that the tuning of the electron-phonon coupling can be effectively decoupled from doping. This work both showcases a feasible method to extract the electron-phonon coupling in superlattices and unveils a potential route for tuning this coupling, which is often associated with superconductivity in SrTiO_{3}-based systems.
Collapse
Affiliation(s)
- D Meyers
- Department of Condensed Matter Physics and Materials Science, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Ken Nakatsukasa
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - Sai Mu
- Department of Condensed Matter Physics and Materials Science, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - Lin Hao
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - Junyi Yang
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - Yue Cao
- Department of Condensed Matter Physics and Materials Science, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Fabbris
- Advanced Photon Source, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - Hu Miao
- Department of Condensed Matter Physics and Materials Science, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Pelliciari
- Photon Science Division, Swiss Light Source, Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland
| | - D McNally
- Photon Science Division, Swiss Light Source, Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland
| | - M Dantz
- Photon Science Division, Swiss Light Source, Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland
| | - E Paris
- Photon Science Division, Swiss Light Source, Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland
| | - E Karapetrova
- Advanced Photon Source, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - Yongseong Choi
- Advanced Photon Source, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - D Haskel
- Advanced Photon Source, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - P Shafer
- Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - E Arenholz
- Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Thorsten Schmitt
- Photon Science Division, Swiss Light Source, Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland
| | - Tom Berlijn
- Center for Nanophase Materials Sciences, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
- Computational Science and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - S Johnston
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
- Joint Institute of Advanced Materials at The University of Tennessee, Knoxville, Tennessee 37996, USA
| | - Jian Liu
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - M P M Dean
- Department of Condensed Matter Physics and Materials Science, Brookhaven National Laboratory, Upton, New York 11973, USA
| |
Collapse
|
36
|
Chi F, Johnston S, Tang X, Chen W, Wang B, Tang S. PSIV-28 Effects of replacing zinc oxide and antibiotics with NeoPrime® on growth performance and plasma and fecal endotoxin concentration in nursery pigs. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.706] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- F Chi
- Amlan International,Shenzhen, China (People’s Republic)
| | - S Johnston
- Amlan International,Shenzhen, China (People’s Republic)
| | - X Tang
- Hunan Agricultural University,Changsha, Hunan, China (People’s Republic)
| | - W Chen
- Hunan Baiyi Group,Liuyang, Hunan, China (People’s Republic)
| | - B Wang
- Hunan Baiyi Group,Liuyang, Hunan, China (People’s Republic)
| | - S Tang
- Amlan International,Shenzhen, China (People’s Republic)
| |
Collapse
|
37
|
Walker SM, Akdis C, Dahlen SE, Djukanovic R, Edwards J, Garcia-Marcos L, Johnston S, Kupczyk M, Martin T, Myles D, Palkonen S, Papadopoulos N, Powell P, Riley J. Building the investment case for asthma R&D: the European Asthma Research and Innovation Partnership argument. Clin Exp Allergy 2018; 46:1136-8. [PMID: 27574040 DOI: 10.1111/cea.12779] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- S M Walker
- Research & Policy, European Asthma Research & Innovation Partnership, Asthma UK, London, UK
| | - C Akdis
- Swiss Institute of Allergy and Asthma Research (SIAF), Medical Faculty, University of Zurich, Zurich, Switzerland
| | - S E Dahlen
- Asthma and Allergy Research, IMM Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - R Djukanovic
- Department of Medicine, Southampton NIHR Respiratory Biomedical Research Unit, University of Southampton, Southampton, UK
| | - J Edwards
- Research & Policy, European Asthma Research & Innovation Partnership, Asthma UK, London, UK
| | - L Garcia-Marcos
- Department of Paediatrics, Paediatric Respiratory and Allergy Units, Arrixaca University Children's Hospital, University of Murcia, Murcia, Spain
| | - S Johnston
- Department of Respiratory Medicine, Airway Disease Infection Section, National Heart and Lung Institute, Imperial College London, London, UK
| | - M Kupczyk
- Medical University of Łódź, Łódź, Poland
| | - T Martin
- Respiratory Therapeutic Area, Respiratory Franchise, Novartis Pharmaceuticals, East Hanover, NJ, USA
| | - D Myles
- Asthma Clinical Discovery, Respiratory Therapy Area Unit, GlaxoSmithKline, Hertfordshire, UK
| | - S Palkonen
- European Federation of Allergy and Airways Diseases Patients' Associations (EFA), Brussels, Belgium
| | - N Papadopoulos
- Allergy Department, University of Athens, Athens, Greece.,Allergy & Paediatric Allergy, University of Manchester, Manchester, UK
| | - P Powell
- European Lung Foundation, Sheffield, UK
| | - J Riley
- European Federation of Allergy and Airways Diseases Patients' Associations (EFA), Brussels, Belgium
| |
Collapse
|
38
|
Cohen EO, Hen O, Piasetzky E, Weinstein LB, Duer M, Schmidt A, Korover I, Hakobyan H, Adhikari S, Akbar Z, Amaryan MJ, Avakian H, Ball J, Barion L, Battaglieri M, Beck A, Bedlinskiy I, Biselli AS, Boiarinov S, Briscoe W, Burkert VD, Cao F, Carman DS, Celentano A, Charles G, Chatagnon P, Chetry T, Ciullo G, Clary BA, Contalbrigo M, Crede V, Cruz Torres R, D'Angelo A, Dashyan N, De Vita R, De Sanctis E, Defurne M, Deur A, Diehl S, Djalali C, Duer M, Dupre R, Egiyan H, Ehrhart M, El Alaoui A, Fassi LE, Eugenio P, Fedotov G, Fersch R, Filippi A, Ghandilyan Y, Giovanetti KL, Girod FX, Golovatch E, Gothe RW, Griffioen KA, Hafidi K, Harrison N, Hauenstein F, Heddle D, Hicks K, Holtrop M, Ireland DG, Ishkhanov BS, Isupov EL, Jenkins D, Jo HS, Johnston S, Kabir ML, Keller D, Khachatryan G, Khachatryan M, Khandaker M, Kim A, Kim W, Klein A, Klein FJ, Korover I, Kubarovsky V, Kuhn SE, Lanza L, Lenisa P, Livingston K, MacGregor IJD, Marchand D, McKinnon B, Mey-Tal Beck S, Meyer CA, Mirazita M, Mokeev V, Montgomery RA, Movsisyan A, Munoz Camacho C, Mustapha B, Nadel-Turonski P, Niccolai S, Niculescu G, Osipenko M, Ostrovidov AI, Paolone M, Paremuzyan R, Pasyuk E, Pogorelko O, Price JW, Prok Y, Protopopescu D, Ripani M, Riser D, Rizzo A, Rosner G, Rossi P, Sabatié F, Schmookler BA, Schumacher RA, Sharabian YG, Sokhan D, Sparveris N, Stepanyan S, Strauch S, Taiuti M, Tan JA, Ungaro M, Voskanyan H, Voutier E, Wang R, Watts DP, Wei X, Wood MH, Zachariou N, Zhang J, Zheng X, Zhao ZW. Center of Mass Motion of Short-Range Correlated Nucleon Pairs studied via the A(e,e^{'}pp) Reaction. Phys Rev Lett 2018; 121:092501. [PMID: 30230869 DOI: 10.1103/physrevlett.121.092501] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Indexed: 06/08/2023]
Abstract
Short-range correlated (SRC) nucleon pairs are a vital part of the nucleus, accounting for almost all nucleons with momentum greater than the Fermi momentum (k_{F}). A fundamental characteristic of SRC pairs is having large relative momenta as compared to k_{F}, and smaller center of mass (c.m.) which indicates a small separation distance between the nucleons in the pair. Determining the c.m. momentum distribution of SRC pairs is essential for understanding their formation process. We report here on the extraction of the c.m. motion of proton-proton (pp) SRC pairs in carbon and, for the first time in heavier and ansymetric nuclei: aluminum, iron, and lead, from measurements of the A(e,e^{'}pp) reaction. We find that the pair c.m. motion for these nuclei can be described by a three-dimensional Gaussian with a narrow width ranging from 140 to 170 MeV/c, approximately consistent with the sum of two mean-field nucleon momenta. Comparison with calculations appears to show that the SRC pairs are formed from mean-field nucleons in specific quantum states.
Collapse
Affiliation(s)
- E O Cohen
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - O Hen
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - E Piasetzky
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - L B Weinstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - M Duer
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - A Schmidt
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - I Korover
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - H Hakobyan
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - S Adhikari
- Florida International University, Miami, Florida 33199, USA
| | - Z Akbar
- Florida State University, Tallahassee, Florida 32306, USA
| | - M J Amaryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Avakian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Ball
- IRFU, CEA, Universit'e Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - L Barion
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | | | - A Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - I Bedlinskiy
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - A S Biselli
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
- Fairfield University, Fairfield Connecticut 06824, USA
| | - S Boiarinov
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - W Briscoe
- Institute for Nuclear Studies, Department of Physics, The George Washington University, Washington DC 20052, USA
| | - V D Burkert
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Cao
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - D S Carman
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Celentano
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - G Charles
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - Pierre Chatagnon
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - G Ciullo
- Universita' di Ferrara, 44121 Ferrara, Italy
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | | | | | - V Crede
- Florida State University, Tallahassee, Florida 32306, USA
| | - R Cruz Torres
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A D'Angelo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Universita' di Roma Tor Vergata, 00133 Rome Italy
| | - N Dashyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - R De Vita
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - E De Sanctis
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - M Defurne
- IRFU, CEA, Universit'e Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - A Deur
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Diehl
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Djalali
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Duer
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - R Dupre
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - H Egiyan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Mathieu Ehrhart
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - A El Alaoui
- Universidad Técnica Federico Santa María, Casilla 110-V Valparaíso, Chile
| | - L El Fassi
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - P Eugenio
- Florida State University, Tallahassee, Florida 32306, USA
| | - G Fedotov
- Ohio University, Athens, Ohio 45701, USA
| | - R Fersch
- Christopher Newport University, Newport News, Virginia 23606, USA
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - A Filippi
- INFN, Sezione di Torino, 10125 Torino, Italy
| | - Y Ghandilyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - K L Giovanetti
- James Madison University, Harrisonburg, Virginia 22807, USA
| | - F X Girod
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - E Golovatch
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - R W Gothe
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - K A Griffioen
- College of William and Mary, Williamsburg, Virginia 23187-8795, USA
| | - K Hafidi
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - N Harrison
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - D Heddle
- Christopher Newport University, Newport News, Virginia 23606, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Hicks
- Ohio University, Athens, Ohio 45701, USA
| | - M Holtrop
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - D G Ireland
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - B S Ishkhanov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - E L Isupov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - D Jenkins
- Virginia Tech, Blacksburg, Virginia 24061-0435, USA
| | - H S Jo
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - S Johnston
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - M L Kabir
- Mississippi State University, Mississippi State, Mississippi 39762-5167, USA
| | - D Keller
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - M Khachatryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - M Khandaker
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - A Kim
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - W Kim
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - A Klein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - F J Klein
- Catholic University of America, Washington, DC 20064, USA
| | - I Korover
- Nuclear Research Centre Negev, Beer-Sheva, Israel
| | - V Kubarovsky
- Rensselaer Polytechnic Institute, Troy, New York 12180-3590, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S E Kuhn
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - L Lanza
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
| | - P Lenisa
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - K Livingston
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | | | - D Marchand
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - B McKinnon
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - S Mey-Tal Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - C A Meyer
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - M Mirazita
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - V Mokeev
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, 119234 Moscow, Russia
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - A Movsisyan
- INFN, Sezione di Ferrara, 44100 Ferrara, Italy
| | - C Munoz Camacho
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - B Mustapha
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Niccolai
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - G Niculescu
- James Madison University, Harrisonburg, Virginia 22807, USA
| | - M Osipenko
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - A I Ostrovidov
- Florida State University, Tallahassee, Florida 32306, USA
| | - M Paolone
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Paremuzyan
- University of New Hampshire, Durham, New Hampshire 03824-3568, USA
| | - E Pasyuk
- Arizona State University, Tempe, Arizona 85287-1504, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - O Pogorelko
- Institute of Theoretical and Experimental Physics, Moscow, 117259, Russia
| | - J W Price
- California State University, Dominguez Hills, Carson, California 90747, USA
| | - Y Prok
- Old Dominion University, Norfolk, Virginia 23529, USA
- University of Virginia, Charlottesville, Virginia 22901, USA
| | | | - M Ripani
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - D Riser
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - A Rizzo
- INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
- Universita' di Roma Tor Vergata, 00133 Rome Italy
| | - G Rosner
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - P Rossi
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Sabatié
- IRFU, CEA, Universit'e Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - B A Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - R A Schumacher
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y G Sharabian
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Sokhan
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - S Stepanyan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Strauch
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Taiuti
- INFN, Sezione di Genova, 16146 Genova, Italy
| | - J A Tan
- Kyungpook National University, Daegu 41566, Republic of Korea
| | - M Ungaro
- Rensselaer Polytechnic Institute, Troy, New York 12180-3590, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Voskanyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | - E Voutier
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - R Wang
- Institut de Physique Nucléaire, CNRS/IN2P3 and Université Paris Sud, Orsay, France
| | - D P Watts
- Edinburgh University, Edinburgh EH9 3JZ, United Kingdom
| | - X Wei
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M H Wood
- Canisius College, Buffalo, New York 14208, USA
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - N Zachariou
- Edinburgh University, Edinburgh EH9 3JZ, United Kingdom
| | - J Zhang
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - X Zheng
- University of Virginia, Charlottesville, Virginia 22901, USA
| | - Z W Zhao
- Duke University, Durham, North Carolina 27708-0305, USA
| |
Collapse
|
39
|
Nocera A, Kumar U, Kaushal N, Alvarez G, Dagotto E, Johnston S. Computing Resonant Inelastic X-Ray Scattering Spectra Using The Density Matrix Renormalization Group Method. Sci Rep 2018; 8:11080. [PMID: 30038401 PMCID: PMC6056525 DOI: 10.1038/s41598-018-29218-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2018] [Accepted: 07/06/2018] [Indexed: 11/08/2022] Open
Abstract
We present a method for computing the resonant inelastic x-ray scattering (RIXS) spectra in one-dimensional systems using the density matrix renormalization group (DMRG) method. By using DMRG to address this problem, we shift the computational bottleneck from the memory requirements associated with exact diagonalization (ED) calculations to the computational time associated with the DMRG algorithm. This approach is then used to obtain RIXS spectra on cluster sizes well beyond state-of-the-art ED techniques. Using this new procedure, we compute the low-energy magnetic excitations observed in Cu L-edge RIXS for the challenging corner shared CuO4 chains, both for large multi-orbital clusters and downfolded t-J chains. We are able to directly compare results obtained from both models defined in clusters with identical momentum resolution. In the strong coupling limit, we find that the downfolded t-J model captures the main features of the magnetic excitations probed by RIXS only after a uniform scaling of the spectra is made.
Collapse
Affiliation(s)
- A Nocera
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, Tennessee, 37996, USA.
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 37831, USA.
| | - U Kumar
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, Tennessee, 37996, USA
- Joint Institute for Advanced Materials, The University of Tennessee, Knoxville, TN, 37996, USA
| | - N Kaushal
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, Tennessee, 37996, USA
| | - G Alvarez
- Computational Science and Engineering Division and Center for Nanophase Materials Sciences, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 37831, USA
| | - E Dagotto
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, Tennessee, 37996, USA
- Materials Science and Technology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, 37831, USA
| | - S Johnston
- Department of Physics and Astronomy, The University of Tennessee, Knoxville, Tennessee, 37996, USA
- Joint Institute for Advanced Materials, The University of Tennessee, Knoxville, TN, 37996, USA
| |
Collapse
|
40
|
Gaudet D, Clohosey D, Hannan J, Goldstein S, Szell N, Komisarek B, Harvey M, Johnston S, Kawaja M, Ghasmlou N, MacKenzie L, Goldstein I, Adams M. 249 Midurethral sling placement disrupts periurethral neurovascular and glandular structures near anterior vaginal wall: Potential role in female sexual dysfunction. J Sex Med 2018. [DOI: 10.1016/j.jsxm.2018.04.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
41
|
Kipps E, Irfan T, Fribbens C, Osin P, Nerurkar A, Mohammed K, Parton M, Johnston S, Turner N, Okines A. Metaplastic Breast Cancer (MBC): A Single Centre Experience. Clin Oncol (R Coll Radiol) 2018. [DOI: 10.1016/j.clon.2018.02.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
42
|
McDonald AD, Jones BJP, Nygren DR, Adams C, Álvarez V, Azevedo CDR, Benlloch-Rodríguez JM, Borges FIGM, Botas A, Cárcel S, Carrión JV, Cebrián S, Conde CAN, Díaz J, Diesburg M, Escada J, Esteve R, Felkai R, Fernandes LMP, Ferrario P, Ferreira AL, Freitas EDC, Goldschmidt A, Gómez-Cadenas JJ, González-Díaz D, Gutiérrez RM, Guenette R, Hafidi K, Hauptman J, Henriques CAO, Hernandez AI, Hernando Morata JA, Herrero V, Johnston S, Labarga L, Laing A, Lebrun P, Liubarsky I, López-March N, Losada M, Martín-Albo J, Martínez-Lema G, Martínez A, Monrabal F, Monteiro CMB, Mora FJ, Moutinho LM, Muñoz Vidal J, Musti M, Nebot-Guinot M, Novella P, Palmeiro B, Para A, Pérez J, Querol M, Repond J, Renner J, Riordan S, Ripoll L, Rodríguez J, Rogers L, Santos FP, Dos Santos JMF, Simón A, Sofka C, Sorel M, Stiegler T, Toledo JF, Torrent J, Tsamalaidze Z, Veloso JFCA, Webb R, White JT, Yahlali N. Demonstration of Single-Barium-Ion Sensitivity for Neutrinoless Double-Beta Decay Using Single-Molecule Fluorescence Imaging. Phys Rev Lett 2018; 120:132504. [PMID: 29694208 DOI: 10.1103/physrevlett.120.132504] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Revised: 02/02/2018] [Indexed: 06/08/2023]
Abstract
A new method to tag the barium daughter in the double-beta decay of ^{136}Xe is reported. Using the technique of single molecule fluorescent imaging (SMFI), individual barium dication (Ba^{++}) resolution at a transparent scanning surface is demonstrated. A single-step photobleach confirms the single ion interpretation. Individual ions are localized with superresolution (∼2 nm), and detected with a statistical significance of 12.9σ over backgrounds. This lays the foundation for a new and potentially background-free neutrinoless double-beta decay technology, based on SMFI coupled to high pressure xenon gas time projection chambers.
Collapse
Affiliation(s)
- A D McDonald
- Department of Physics, University of Texas at Arlington, Arlington, Texas 76019, USA
| | - B J P Jones
- Department of Physics, University of Texas at Arlington, Arlington, Texas 76019, USA
| | - D R Nygren
- Department of Physics, University of Texas at Arlington, Arlington, Texas 76019, USA
| | - C Adams
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - V Álvarez
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - C D R Azevedo
- Institute of Nanostructures, Nanomodelling and Nanofabrication (i3N), Universidade de Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal
| | - J M Benlloch-Rodríguez
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - F I G M Borges
- LIP, Department of Physics, University of Coimbra, P-3004 516 Coimbra, Portugal
| | - A Botas
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - S Cárcel
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - J V Carrión
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - S Cebrián
- Laboratorio de Física Nuclear y Astropartículas, Universidad de Zaragoza, Calle Pedro Cerbuna, 12, 50009 Zaragoza, Spain
| | - C A N Conde
- LIP, Department of Physics, University of Coimbra, P-3004 516 Coimbra, Portugal
| | - J Díaz
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - M Diesburg
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Escada
- LIP, Department of Physics, University of Coimbra, P-3004 516 Coimbra, Portugal
| | - R Esteve
- Instituto de Instrumentación para Imagen Molecular (I3M), Centro Mixto CSIC-Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain
| | - R Felkai
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - L M P Fernandes
- LIBPhys, Physics Department, University of Coimbra, Rua Larga, 3004-516 Coimbra, Portugal
| | - P Ferrario
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - A L Ferreira
- Institute of Nanostructures, Nanomodelling and Nanofabrication (i3N), Universidade de Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal
| | - E D C Freitas
- LIBPhys, Physics Department, University of Coimbra, Rua Larga, 3004-516 Coimbra, Portugal
| | - A Goldschmidt
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720, USA
| | - J J Gómez-Cadenas
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - D González-Díaz
- Instituto Gallego de Física de Altas Energías, Univ. de Santiago de Compostela, Campus sur, Rúa Xosé María Suárez Núñez, s/n, 15782 Santiago de Compostela, Spain
| | - R M Gutiérrez
- Centro de Investigación en Ciencias Básicas y Aplicadas, Universidad Antonio Nariño, Sede Circunvalar, Carretera 3 Este No. 47 A-15, Bogotá, Colombia
| | - R Guenette
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - K Hafidi
- Argonne National Laboratory, Argonne Illinois 60439, USA
| | - J Hauptman
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011-3160, USA
| | - C A O Henriques
- LIBPhys, Physics Department, University of Coimbra, Rua Larga, 3004-516 Coimbra, Portugal
| | - A I Hernandez
- Centro de Investigación en Ciencias Básicas y Aplicadas, Universidad Antonio Nariño, Sede Circunvalar, Carretera 3 Este No. 47 A-15, Bogotá, Colombia
| | - J A Hernando Morata
- Instituto Gallego de Física de Altas Energías, Univ. de Santiago de Compostela, Campus sur, Rúa Xosé María Suárez Núñez, s/n, 15782 Santiago de Compostela, Spain
| | - V Herrero
- Instituto de Instrumentación para Imagen Molecular (I3M), Centro Mixto CSIC-Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain
| | - S Johnston
- Argonne National Laboratory, Argonne Illinois 60439, USA
| | - L Labarga
- Departamento de Física Teórica, Universidad Autónoma de Madrid, Campus de Cantoblanco, 28049 Madrid, Spain
| | - A Laing
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - P Lebrun
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - I Liubarsky
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - N López-March
- Department of Physics, University of Texas at Arlington, Arlington, Texas 76019, USA
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - M Losada
- Centro de Investigación en Ciencias Básicas y Aplicadas, Universidad Antonio Nariño, Sede Circunvalar, Carretera 3 Este No. 47 A-15, Bogotá, Colombia
| | - J Martín-Albo
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - G Martínez-Lema
- Instituto Gallego de Física de Altas Energías, Univ. de Santiago de Compostela, Campus sur, Rúa Xosé María Suárez Núñez, s/n, 15782 Santiago de Compostela, Spain
| | - A Martínez
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - F Monrabal
- Department of Physics, University of Texas at Arlington, Arlington, Texas 76019, USA
| | - C M B Monteiro
- LIBPhys, Physics Department, University of Coimbra, Rua Larga, 3004-516 Coimbra, Portugal
| | - F J Mora
- Instituto de Instrumentación para Imagen Molecular (I3M), Centro Mixto CSIC-Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain
| | - L M Moutinho
- Institute of Nanostructures, Nanomodelling and Nanofabrication (i3N), Universidade de Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal
| | - J Muñoz Vidal
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - M Musti
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - M Nebot-Guinot
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - P Novella
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - B Palmeiro
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - A Para
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Pérez
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - M Querol
- Instituto de Instrumentación para Imagen Molecular (I3M), Centro Mixto CSIC-Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain
| | - J Repond
- Argonne National Laboratory, Argonne Illinois 60439, USA
| | - J Renner
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - S Riordan
- Argonne National Laboratory, Argonne Illinois 60439, USA
| | - L Ripoll
- Escola Politècnica Superior, Universitat de Girona, Av. Montilivi, s/n, 17071 Girona, Spain
| | - J Rodríguez
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - L Rogers
- Department of Physics, University of Texas at Arlington, Arlington, Texas 76019, USA
| | - F P Santos
- LIP, Department of Physics, University of Coimbra, P-3004 516 Coimbra, Portugal
| | - J M F Dos Santos
- LIBPhys, Physics Department, University of Coimbra, Rua Larga, 3004-516 Coimbra, Portugal
| | - A Simón
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - C Sofka
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - M Sorel
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - T Stiegler
- Department of Physics and Astronomy, Texas A&M University, College Station, Texas 77843-4242, USA
| | - J F Toledo
- Instituto de Instrumentación para Imagen Molecular (I3M), Centro Mixto CSIC-Universitat Politècnica de València, Camino de Vera s/n, 46022 Valencia, Spain
| | - J Torrent
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| | - Z Tsamalaidze
- Joint Institute for Nuclear Research (JINR), Joliot-Curie 6, 141980 Dubna, Russia
| | - J F C A Veloso
- Institute of Nanostructures, Nanomodelling and Nanofabrication (i3N), Universidade de Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal
| | - R Webb
- Department of Physics and Astronomy, Texas A&M University, College Station, Texas 77843-4242, USA
| | - J T White
- Department of Physics and Astronomy, Texas A&M University, College Station, Texas 77843-4242, USA
| | - N Yahlali
- Instituto de Física Corpuscular (IFIC), CSIC & Universitat de València, Calle Catedrático José Beltrán, 2, 46980 Paterna, Valencia, Spain
| |
Collapse
|
43
|
El-Bouri K, Johnston S, Rees E, Thomas I, Bome-Mannathoko N, Jones C, Reid M, Ben-Ismaeil B, Davies AP, Harris LG, Mack D. Comparison of bacterial identification by MALDI-TOF mass spectrometry and conventional diagnostic microbiology methods: agreement, speed and cost implications. Br J Biomed Sci 2018. [DOI: 10.1080/09674845.2012.12002436] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- K. El-Bouri
- Public Health Wales Microbiology Laboratory ABM Swansea, Singleton Hospital, Abertawe-Bro Morgannwg University Health Board, Swansea, United Kingdom
| | - S. Johnston
- Public Health Wales Microbiology Laboratory ABM Swansea, Singleton Hospital, Abertawe-Bro Morgannwg University Health Board, Swansea, United Kingdom
| | - E. Rees
- Public Health Wales Microbiology Laboratory ABM Swansea, Singleton Hospital, Abertawe-Bro Morgannwg University Health Board, Swansea, United Kingdom
| | - I. Thomas
- Public Health Wales Microbiology Laboratory ABM Swansea, Singleton Hospital, Abertawe-Bro Morgannwg University Health Board, Swansea, United Kingdom
| | - N. Bome-Mannathoko
- Medical Microbiology and Infectious Diseases, Institute of Life Science, School of Medicine, Swansea University, Swansea, United Kingdom
| | - C. Jones
- Medical Microbiology and Infectious Diseases, Institute of Life Science, School of Medicine, Swansea University, Swansea, United Kingdom
| | - M. Reid
- Public Health Wales Microbiology Laboratory ABM Swansea, Singleton Hospital, Abertawe-Bro Morgannwg University Health Board, Swansea, United Kingdom
- Medical Microbiology and Infectious Diseases, Institute of Life Science, School of Medicine, Swansea University, Swansea, United Kingdom
| | - B. Ben-Ismaeil
- Public Health Wales Microbiology Laboratory ABM Swansea, Singleton Hospital, Abertawe-Bro Morgannwg University Health Board, Swansea, United Kingdom
| | - A. P. Davies
- Public Health Wales Microbiology Laboratory ABM Swansea, Singleton Hospital, Abertawe-Bro Morgannwg University Health Board, Swansea, United Kingdom
- Medical Microbiology and Infectious Diseases, Institute of Life Science, School of Medicine, Swansea University, Swansea, United Kingdom
| | - L. G. Harris
- Medical Microbiology and Infectious Diseases, Institute of Life Science, School of Medicine, Swansea University, Swansea, United Kingdom
| | - D. Mack
- Public Health Wales Microbiology Laboratory ABM Swansea, Singleton Hospital, Abertawe-Bro Morgannwg University Health Board, Swansea, United Kingdom
- Medical Microbiology and Infectious Diseases, Institute of Life Science, School of Medicine, Swansea University, Swansea, United Kingdom
| |
Collapse
|
44
|
Di Leo A, Dickler M, Sledge GW, Toi M, Forrester T, Nanda S, Koustenis A, Bourayou N, Johnston S. Abstract P5-21-02: Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Abemaciclib is an oral, selective inhibitor of cyclin-dependent kinases 4 & 6 that is dosed on a twice daily continuous schedule. In patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), abemaciclib has demonstrated clinical efficacy with a tolerable safety profile when administered as monotherapy in MONARCH 1 (NCT02102490), in combination with fulvestrant in MONARCH 2 (NCT02107703), and in combination with non-steroidal aromatase inhibitors (NSAI) in MONARCH 3 (NCT02246621). Inducing tumor response and delaying disease progression is of critical need in pts with liver metastases (mets).
Methods:
An exploratory subgroup analysis was conducted in pts with liver mets at baseline across the MONARCH 1, 2, and 3 studies. All pts had HR+, HER2- ABC. The primary endpoint of MONARCH 1 was objective response rate (ORR), and the primary endpoint of MONARCH 2 and 3 was investigator-assessed progression-free survival (PFS). Analysis methods for these endpoints were previously described. Key enrollment criteria and dosing information are listed in Table 1.
Table 1. Eligibility criteria and dosing information for the MONARCH 1, 2, and 3 studiesKey enrollment criteriaMONARCH 1MONARCH 2MONARCH 3Prior endocrine therapyProgressed on or after ETProgressed while receiving adjuvant or first-line ET, or ≤ 12 months from the end of adjuvant ETET naïve or disease relapse >12 months after (neo)adjuvant ETChemotherapy regimens in advanced setting1 or 200Visceral crisisNo restrictionNot permittedNot permittedDose and Schedule abemaciclib200 mg, twice daily, continuous150 mg1, twice daily, continuous150 mg, twice daily, continuousfulvestrant-500 mg, per label-anastrozole2--1 mg, dailyletrozole2--2.5 mg, daily1post-amendment; 2physician's choice of NSAI (anastrozole or letrozole); ET: endocrine therapy
Results:
Efficacy results of pts with liver mets are described in Table 2. The most frequent adverse events observed in pts with liver mets in MONARCH 1 were diarrhea, nausea, and fatigue and in the abemaciclib arms of MONARCH 2 and 3 were diarrhea, neutropenia, and nausea.
Table 2. PFS and response rates of pts with liver mets in MONARCH 1, 2, and 3 MONARCH 1MONARCH 2 abemaciclib armMONARCH 2 placebo armMONARCH 3 abemaciclib armMONARCH 3 placebo armPts with liver mets, n93115594830PFS, HR (95% CI)N/A.45 (.31, .64).47 (.25, .87)Median PFS, months5.611.63.115.07.2ORR, n (%)20 (21.5)54 (47.0)9 (15.3)26 (54.2)6 (20.0)CBR, n (%)39 (41.9)77 (67.0)21 (35.6)32 (66.7)12 (40.0)CBR: clinical benefit rate (complete response [CR] + partial response [PR] + stable disease ≥6 months); HR: hazard ratio; ORR: objective response rate (CR+PR); PFS: progression-free survival; pts: patients
Conclusions:
The results suggest that the combination of abemaciclib and endocrine therapy was an effective treatment option in pts with liver metastases, a population deriving modest benefit from single-agent endocrine therapy. Tolerability results were generally consistent with the safety populations previously reported for each study.
Citation Format: Di Leo A, Dickler M, Sledge GW, Toi M, Forrester T, Nanda S, Koustenis A, Bourayou N, Johnston S. Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-02.
Collapse
Affiliation(s)
- A Di Leo
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Dickler
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - GW Sledge
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Toi
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - T Forrester
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - S Nanda
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Koustenis
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - N Bourayou
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - S Johnston
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| |
Collapse
|
45
|
Harbeck N, Dieras V, Finn R, Gelmon KA, Walshe JM, Shparyk Y, Mori A, Lui DR, Bhattacharyya H, Iyer S, Johnston S, Rugo HS. Abstract P5-19-01: Impact of palbociclib plus letrozole on patient-reported general health status compared with letrozole alone in ER+/HER2- advanced/metastatic breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-19-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Palbociclib plus letrozole significantly improved progression-free survival (PFS) compared with letrozole plus placebo in treatment-naive postmenopausal patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) in the phase 3 PALOMA-2 trial. Here, we compare patient-reported general health status with extended (max 53 cycles) follow-up (data cut off May31st, 2017) (Pfizer: NCT01740427).
METHODS: PALOMA-2 randomized patients 2:1 to palbociclib + letrozole (n=444) or placebo + letrozole (n=222). Patient-reported outcomes were assessed at baseline, day 1 of cycles 1, 2, and 3, and day 1 of every other cycle from cycle 5 until the end of treatment using the EuroQol 5-Dimension Questionnaire (EQ-5D). The EQ-5D is a standardized measure of health status that consists of a descriptive system comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression rated at 3 levels (no, some, or extreme problems) and a single index score for health status (ranges generally from 0 [dead] to 1 [full health]) calculated using a standard algorithm. In addition, a visual analog scale (VAS) measured self-rated health status from 0 (worst imaginable) to 100 (best imaginable). Repeated measures mixed-effects analyses were performed to compare overall index and VAS scores between treatments, controlling for baseline.
RESULTS: Completion rates at baseline were >95% in each group. The mean (SD) scores at baseline were comparable between palbociclib plus letrozole and letrozole alone for the VAS (71.3 [21.2] vs 72.3 [19.8]) and the EQ-5D index scores (0.70 [0.25]) vs (0.73 [0.21]). Median follow up was 38 months for palbociclib plus letrozole and 37 months for letrozole only. No statistically significant difference in overall change from baseline in general health status was observed between the treatment arms. The proportion of patients reporting the presence of a problem at baseline was similar for palbociclib plus letrozole and letrozole, respectively: mobility (39% vs 39%), self-care (12% vs 12%), usual activities (44% vs 39%), pain (69% vs 65%), and anxiety/depression (54% vs 54%). No statistically significant difference in overall mean EQ-5D index scores (0.73 vs. 0.71) was observed between the treatment arms.
CONCLUSION: Addition of palbociclib to letrozole maintained general health status and EQ-5D index scores in ER+ HER2- advanced/metastatic breast cancer with no statistically significant differences observed compared to letrozole alone.
Citation Format: Harbeck N, Dieras V, Finn R, Gelmon KA, Walshe JM, Shparyk Y, Mori A, Lui DR, Bhattacharyya H, Iyer S, Johnston S, Rugo HS. Impact of palbociclib plus letrozole on patient-reported general health status compared with letrozole alone in ER+/HER2- advanced/metastatic breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-19-01.
Collapse
Affiliation(s)
- N Harbeck
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - V Dieras
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - R Finn
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - KA Gelmon
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - JM Walshe
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - Y Shparyk
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - A Mori
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - DR Lui
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - H Bhattacharyya
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - S Iyer
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - S Johnston
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| | - HS Rugo
- Brustzentrum der Universität München (LMU), Marchioninistrasse 15, Munchen, Germany; Institut Curie, Paris, France; University of California, Los Angeles, CA; 5British Columbia Cancer Agency-Vancouver Centre, Vancouver, BC, Canada; Cancer Trials Ireland, Dublin, Ireland; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine; Pfizer s.r.l., Milan, Italy; Pfizer, Inc, La Jolla, CA; Pfizer, Inc, New York, NY; The Royal Marsden NHS Foundation, London, United Kingdom; University of California, San Francisco, CA
| |
Collapse
|
46
|
Rastogi P, Toi M, Harbeck N, Bourayou N, Frenzel M, Johnston S. Abstract OT3-05-05: MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2- breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-05-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Abemaciclib, an oral, selective inhibitor of cyclin-dependent kinases 4 and 6 dosed on a twice daily continuous schedule, has demonstrated clinical efficacy and tolerability in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer when administered as monotherapy (MONARCH 1) and in combination with endocrine therapy (ET) in MONARCH 2 and MONARCH 3. In neoMONARCH, abemaciclib plus anastrozole as neoadjuvant therapy reduced the breast tumor cell proliferation marker Ki67 to a greater extent than anastrozole alone after 2 weeks of treatment. Endocrine monotherapy is the current standard of care in the adjuvant setting. However, a proportion of pts relapse despite this therapy. A population with a higher risk of recurrence (15% at 5 years) may be identified based on the clinical and pathological characteristics of disease. Optimizing adjuvant therapy for these pts is an important need.
Trial Design: MonarchE (NCT03155997) is a multicenter, randomized, open-label Phase 3 trial that will evaluate the potential for abemaciclib to enhance adjuvant ET. Pts will be randomized 1:1 to abemaciclib 150 mg twice daily continuous schedule plus standard of care (SOC) adjuvant ET versus SOC adjuvant ET alone and stratified by prior chemotherapy (neoadjuvant, adjuvant, or none), menopausal status (pre- or post-), and region (N. America/Europe, Asia, or other). Pts may have started ET within 8 weeks prior to randomization. Pts will receive abemaciclib for up to 2 years in combination with ET per physician's choice (such as tamoxifen or an aromatase inhibitor, +/- ovarian suppression). ET alone will be continued as clinically indicated. All randomized pts will be followed for a total of 10 years.
Eligibility Criteria: Eligible pts (male or female) must have early stage resected HR+, HER2- invasive breast cancer with either ≥ 4 positive pathological axillary lymph nodes (pALNs), or 1 to 3 positive pALNs and at least one of the following high risk markers: primary tumor size ≥5 cm, histological grade 3 tumor, or centrally assessed Ki67 index of ≥20% (in a subset of pts). Pts must have completed definitive locoregional therapy (+/- (neo)adjuvant chemotherapy) and be randomized no more than 12 weeks after completion of last non-ET (surgery, chemotherapy, or radiotherapy). Pts must have tumor tissue available for biomarker analysis prior to randomization.
Specific Aims: The primary objective of monarchE is to evaluate invasive disease-free survival (IDFS) per the STEEP System.1 Secondary objectives include evaluation of IDFS in pts with Ki67 index of ≥20%, distant relapse-free survival, overall survival, safety, pharmacokinetics, and pt health outcomes.
Statistical Methods: Assuming an IDFS hazard ratio of .73, the study is powered to approximately 80% to test the superiority of abemaciclib plus standard ET at a 1-sided α=0.025 using a stratified log-rank test.
Target accrual: Approximately 3580 pts
Contact information: 1-877-285-4559
Reference:
1. Hudis et al. J Clin Oncol. 2007;25(15):2127-2132.
Citation Format: Rastogi P, Toi M, Harbeck N, Bourayou N, Frenzel M, Johnston S. MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2- breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-05-05.
Collapse
Affiliation(s)
- P Rastogi
- University of Pittsburgh Medical Center, Pittsburgh, PA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Breast Center, University of Munich (LMU), Munich, Germany; Eli Lilly and Company, Paris, France; Eli Lilly and Company, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Toi
- University of Pittsburgh Medical Center, Pittsburgh, PA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Breast Center, University of Munich (LMU), Munich, Germany; Eli Lilly and Company, Paris, France; Eli Lilly and Company, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - N Harbeck
- University of Pittsburgh Medical Center, Pittsburgh, PA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Breast Center, University of Munich (LMU), Munich, Germany; Eli Lilly and Company, Paris, France; Eli Lilly and Company, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - N Bourayou
- University of Pittsburgh Medical Center, Pittsburgh, PA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Breast Center, University of Munich (LMU), Munich, Germany; Eli Lilly and Company, Paris, France; Eli Lilly and Company, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Frenzel
- University of Pittsburgh Medical Center, Pittsburgh, PA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Breast Center, University of Munich (LMU), Munich, Germany; Eli Lilly and Company, Paris, France; Eli Lilly and Company, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - S Johnston
- University of Pittsburgh Medical Center, Pittsburgh, PA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Breast Center, University of Munich (LMU), Munich, Germany; Eli Lilly and Company, Paris, France; Eli Lilly and Company, Indianapolis, IN; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| |
Collapse
|
47
|
Garcia-Murillas I, Proszek P, Fribbens C, Yuan L, Bye H, Hubank M, Jiang J, Yuang S, Palma J, Johnston S, Ring A, Turner N. Abstract P2-02-17: Circulating tumor DNA analysis with ultra-high sensitivity sequencing in metastatic breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-02-17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction.
Circulating tumor DNA analysis has the potential to transform the clinical management of patients with breast cancer. We assessed the accuracy of ultra-high sensitivity ctDNA testing in patients with advanced breast cancer.
Methods.
From a prospective tissue collection study, we identified 25 patients with a contemporaneous metastatic tissue biopsy and plasma for ctDNA testing. Tumour DNA from the metastatic tissue biopsy was sequenced with a validated clinical hybrid capture panel, while plasma cell free DNA was sequenced with AVENIO ctDNA technology – a molecular barcoded duplex sequencing based on CAPPseq technology. Sample collection is on-going and results from the full concordance series will be presented at the conference.
Results.
Circulating tumour DNA was detectable in 87% (20/23) of patients, with at least one variant from tissue sequencing identified in plasma. There was overall high agreement between tissue and plasma sequencing. The sensitivity of plasma testing for variants identified in tumour, positive percent agreement, was 75% (24/32). Plasma testing revealed a diversity of sub-clonal mutations including polyclonal ESR1, polyclonal FGFR2 and FGFR3 mutations, rare KRAS mutations, and TSC1 and MSH2 inactivating mutations.
Conclusions.
Circulating tumour DNA testing with molecular barcoded duplex sequencing offers high sensitivity for tumour variant detection. The extent of sub-clonal resistance mutations identified emphasises the genetic diversity of advanced breast cancer.
Citation Format: Garcia-Murillas I, Proszek P, Fribbens C, Yuan L, Bye H, Hubank M, Jiang J, Yuang S, Palma J, Johnston S, Ring A, Turner N. Circulating tumor DNA analysis with ultra-high sensitivity sequencing in metastatic breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-02-17.
Collapse
Affiliation(s)
- I Garcia-Murillas
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Roche Sequencing Solutions, Pleasanton, CA
| | - P Proszek
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Roche Sequencing Solutions, Pleasanton, CA
| | - C Fribbens
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Roche Sequencing Solutions, Pleasanton, CA
| | - L Yuan
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Roche Sequencing Solutions, Pleasanton, CA
| | - H Bye
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Roche Sequencing Solutions, Pleasanton, CA
| | - M Hubank
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Roche Sequencing Solutions, Pleasanton, CA
| | - J Jiang
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Roche Sequencing Solutions, Pleasanton, CA
| | - S Yuang
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Roche Sequencing Solutions, Pleasanton, CA
| | - J Palma
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Roche Sequencing Solutions, Pleasanton, CA
| | - S Johnston
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Roche Sequencing Solutions, Pleasanton, CA
| | - A Ring
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Roche Sequencing Solutions, Pleasanton, CA
| | - N Turner
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; Roche Sequencing Solutions, Pleasanton, CA
| |
Collapse
|
48
|
Gaudet D, Clohosey D, Goldstein S, Szell N, Komisaruk B, Hannan J, Harvey M, Johnston S, Kawaja M, Ghasemlou N, MacKenzie L, Goldstein I, Adams M. 010 Simulation of Mid-Urethral Incontinence Sling Surgery Using Cadavers: Impact on Innervation and Glandular Tissue. J Sex Med 2018. [DOI: 10.1016/j.jsxm.2017.11.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
49
|
Cameron AD, Champion DJ, Kramer M, Bailes M, Barr ED, Bassa CG, Bhandari S, Bhat NDR, Burgay M, Burke-Spolaor S, Eatough RP, Flynn CML, Freire PCC, Jameson A, Johnston S, Karuppusamy R, Keith MJ, Levin L, Lorimer DR, Lyne AG, McLaughlin MA, Ng C, Petroff E, Possenti A, Ridolfi A, Stappers BW, van Straten W, Tauris TM, Tiburzi C, Wex N. The High Time Resolution Universe Pulsar Survey – XIII. PSR J1757−1854, the most accelerated binary pulsar. ACTA ACUST UNITED AC 2018. [DOI: 10.1093/mnrasl/sly003] [Citation(s) in RCA: 62] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- A D Cameron
- Max-Planck-Institut für Radioastronomie, Auf dem Hügel 69, D-53121 Bonn, Germany
| | - D J Champion
- Max-Planck-Institut für Radioastronomie, Auf dem Hügel 69, D-53121 Bonn, Germany
| | - M Kramer
- Max-Planck-Institut für Radioastronomie, Auf dem Hügel 69, D-53121 Bonn, Germany
- Jodrell Bank Center for Astrophysics, University of Manchester, Alan Turing Building, Oxford Road, Manchester M13 9PL, UK
| | - M Bailes
- Centre for Astrophysics and Supercomputing, Swinburne University of Technology, Mail H39, PO Box 218, VIC 3122, Australia
- ARC Center of Excellence for All-Sky Astronomy (CAASTRO), Swinburne University of Technology, Mail H30, PO Box 218, VIC 3122, Australia
- ARC Center of Excellence for Gravitational Wave Discovery (OzGrav), Swinburne University of Technology, Mail H11, PO Box 218, VIC 3122, Australia
| | - E D Barr
- Max-Planck-Institut für Radioastronomie, Auf dem Hügel 69, D-53121 Bonn, Germany
| | - C G Bassa
- ASTRON, the Netherlands Institute for Radio Astronomy, Postbus 2, NL-7990 AA Dwingeloo, the Netherlands
| | - S Bhandari
- Centre for Astrophysics and Supercomputing, Swinburne University of Technology, Mail H39, PO Box 218, VIC 3122, Australia
- ARC Center of Excellence for All-Sky Astronomy (CAASTRO), Swinburne University of Technology, Mail H30, PO Box 218, VIC 3122, Australia
| | - N D R Bhat
- ARC Center of Excellence for All-Sky Astronomy (CAASTRO), Swinburne University of Technology, Mail H30, PO Box 218, VIC 3122, Australia
- International Centre for Radio Astronomy Research, Curtin University, Bentley, WA 6102, Australia
| | - M Burgay
- INAF - Osservatorio Astronomico di Cagliari, Via della Scienza 5, I-09047 Selargius (CA), Italy
| | - S Burke-Spolaor
- Department of Physics and Astronomy, West Virginia University, PO Box 6315, Morgantown, WV 26506, USA
- Center for Gravitational Waves and Cosmology, West Virginia University, Chestnut Ridge Research Building, Morgantown, WV 26505, USA
| | - R P Eatough
- Max-Planck-Institut für Radioastronomie, Auf dem Hügel 69, D-53121 Bonn, Germany
| | - C M L Flynn
- Centre for Astrophysics and Supercomputing, Swinburne University of Technology, Mail H39, PO Box 218, VIC 3122, Australia
| | - P C C Freire
- Max-Planck-Institut für Radioastronomie, Auf dem Hügel 69, D-53121 Bonn, Germany
| | - A Jameson
- Centre for Astrophysics and Supercomputing, Swinburne University of Technology, Mail H39, PO Box 218, VIC 3122, Australia
- ARC Center of Excellence for All-Sky Astronomy (CAASTRO), Swinburne University of Technology, Mail H30, PO Box 218, VIC 3122, Australia
| | - S Johnston
- CSIRO Astronomy and Space Science, Australia Telescope National Facility, PO Box 76, Epping, NSW 1710, Australia
| | - R Karuppusamy
- Max-Planck-Institut für Radioastronomie, Auf dem Hügel 69, D-53121 Bonn, Germany
| | - M J Keith
- Jodrell Bank Center for Astrophysics, University of Manchester, Alan Turing Building, Oxford Road, Manchester M13 9PL, UK
| | - L Levin
- Jodrell Bank Center for Astrophysics, University of Manchester, Alan Turing Building, Oxford Road, Manchester M13 9PL, UK
| | - D R Lorimer
- Department of Physics and Astronomy, West Virginia University, PO Box 6315, Morgantown, WV 26506, USA
| | - A G Lyne
- Jodrell Bank Center for Astrophysics, University of Manchester, Alan Turing Building, Oxford Road, Manchester M13 9PL, UK
| | - M A McLaughlin
- Department of Physics and Astronomy, West Virginia University, PO Box 6315, Morgantown, WV 26506, USA
| | - C Ng
- Department of Physics and Astronomy, University of British Columbia, 6224 Agricultural Road, Vancouver, BC V6T 1Z1, Canada
| | - E Petroff
- ASTRON, the Netherlands Institute for Radio Astronomy, Postbus 2, NL-7990 AA Dwingeloo, the Netherlands
| | - A Possenti
- INAF - Osservatorio Astronomico di Cagliari, Via della Scienza 5, I-09047 Selargius (CA), Italy
| | - A Ridolfi
- Max-Planck-Institut für Radioastronomie, Auf dem Hügel 69, D-53121 Bonn, Germany
| | - B W Stappers
- Jodrell Bank Center for Astrophysics, University of Manchester, Alan Turing Building, Oxford Road, Manchester M13 9PL, UK
| | - W van Straten
- Centre for Astrophysics and Supercomputing, Swinburne University of Technology, Mail H39, PO Box 218, VIC 3122, Australia
- ARC Center of Excellence for All-Sky Astronomy (CAASTRO), Swinburne University of Technology, Mail H30, PO Box 218, VIC 3122, Australia
- Institute for Radio Astronomy & Space Research, Auckland University of Technology, Private Bag 92006, Auckland 1142, New Zealand
| | - T M Tauris
- Max-Planck-Institut für Radioastronomie, Auf dem Hügel 69, D-53121 Bonn, Germany
- Argelander-Insitut für Astronomie, Universität Bonn, Auf dem Hügel 71, D-53121 Bonn, Germany
| | - C Tiburzi
- Max-Planck-Institut für Radioastronomie, Auf dem Hügel 69, D-53121 Bonn, Germany
- Fakultät für Physik, Universität Bielefeld, Postfach 100131, D-33501 Bielefeld, Germany
| | - N Wex
- Max-Planck-Institut für Radioastronomie, Auf dem Hügel 69, D-53121 Bonn, Germany
| |
Collapse
|
50
|
Fribbens C, Garcia Murillas I, Beaney M, Hrebien S, O'Leary B, Kilburn L, Howarth K, Epstein M, Green E, Rosenfeld N, Ring A, Johnston S, Turner N. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Ann Oncol 2018; 29:145-153. [PMID: 29045530 PMCID: PMC6264798 DOI: 10.1093/annonc/mdx483] [Citation(s) in RCA: 101] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Background Selection of resistance mutations may play a major role in the development of endocrine resistance. ESR1 mutations are rare in primary breast cancer but have high prevalence in patients treated with aromatase inhibitors (AI) for advanced breast cancer. We investigated the evolution of genetic resistance to the first-line AI therapy using sequential ctDNA sampling in patients with advanced breast cancer. Patients and methods Eighty-three patients on the first-line AI therapy for metastatic breast cancer were enrolled in a prospective study. Plasma samples were collected every 3 months to disease progression and ctDNA analysed by digital droplet PCR and enhanced tagged-amplicon sequencing (eTAm-Seq). Mutations identified in progression samples by sequencing were tracked back through samples before progression to study the evolution of mutations on therapy. The frequency of novel mutations was validated in an independent cohort of available baseline plasma samples in the Study of Faslodex versus Exemestane with or without Arimidex (SoFEA) trial, which enrolled patients with prior sensitivity to AI. Results Of the 39 patients who progressed on the first-line AI, 56.4% (22/39) had ESR1 mutations detectable at progression, which were polyclonal in 40.9% (9/22) patients. In serial tracking, ESR1 mutations were detectable median 6.7 months (95% confidence interval 3.7-NA) before clinical progression. Utilising eTAm-Seq ctDNA sequencing of progression plasma, ESR1 mutations were demonstrated to be sub-clonal in 72.2% (13/18) patients. Mutations in RAS genes were identified in 15.4% (6/39) of progressing patients (4 KRAS, 1 HRAS, 1 NRAS). In SoFEA, KRAS mutations were detected in 21.2% (24/113) patients although there was no evidence that KRAS mutation status was prognostic for progression free or overall survival. Conclusions Cancers progressing on the first-line AI show high levels of genetic heterogeneity, with frequent sub-clonal mutations. Sub-clonal KRAS mutations are found at high frequency. The genetic diversity of AI resistant cancers may limit subsequent targeted therapy approaches.
Collapse
Affiliation(s)
- C Fribbens
- Breast Cancer Now Research Centre, Institute of Cancer Research, London, UK
- Breast Unit, Royal Marsden Hospital, London, UK
| | - I Garcia Murillas
- Breast Cancer Now Research Centre, Institute of Cancer Research, London, UK
| | - M Beaney
- Breast Cancer Now Research Centre, Institute of Cancer Research, London, UK
| | - S Hrebien
- Breast Cancer Now Research Centre, Institute of Cancer Research, London, UK
| | - B O'Leary
- Breast Cancer Now Research Centre, Institute of Cancer Research, London, UK
| | - L Kilburn
- Institute of Cancer Research Clinical Trials & Statistics Unit (ICR-CTSU), London, UK
| | - K Howarth
- Inivata Ltd., The Portway, Granta Park, Great Abington, UK
| | - M Epstein
- Inivata Ltd., The Portway, Granta Park, Great Abington, UK
| | - E Green
- Inivata Ltd., The Portway, Granta Park, Great Abington, UK
| | - N Rosenfeld
- Inivata Ltd., The Portway, Granta Park, Great Abington, UK
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
- Cancer Research UK Major Centre, Robinson Way, Cambridge, UK
| | - A Ring
- Breast Unit, Royal Marsden Hospital, London, UK
| | - S Johnston
- Breast Unit, Royal Marsden Hospital, London, UK
| | - N Turner
- Breast Cancer Now Research Centre, Institute of Cancer Research, London, UK
- Breast Unit, Royal Marsden Hospital, London, UK
| |
Collapse
|